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INTRODUCTION 
  
 The field of Pharmacognosy has well advanced in the past centuries. Natural 
products from the medicinal plant source are the main cast of modern drugs in clinical 
use
1
.  
 
Hippocrates says that
2 
  
 ” Life is short, and the art long; the occasion fleeting, experience 
fallacious; and judgment difficult”.   
 
 Millions of people in the third world have used and will always use herbal 
medicines because they believe in them and regard them as their Medicine, in contrast 
to the “Allopathic” (conventional medicine) brought it form “outside”.  
 
In western countries, there is now an increased use of Herbal medicines, 
largely because of a belief that powerful synthetic agents used in western medicine 
can exert more unwanted side effects and are too often used indiscriminately and 
irrationally. 
 
“Nature is the finest doctor, India  is a medicinal meadow with over 7500 
medicinal plants that cure naturally. Reviving this ancient, effective and rich 
medicinal heritage is the right way to improve the health status of the people”.  
 
It is estimated that 2% of landmass has 25% of biodiversity and 7000 species 
of herbs are available in different ecofloristic regions of India. Also 159 
Pharmaceutical companies are utilizing about 300 species of herbs in their 
formulations and the production has recently increased from Rs 100 crore in 1991 to 
Rs 400 crore
3
.   
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Plants have curative measures for all the ailments but man has to discover it 
out. Herbs act in almost magical and astonishing ways. However, the ultimate 
objective of this is that they should interest directly with our body chemistry. Their 
active constituents must be absorbed into the body for deriving the required benefits. 
Once they are absorbed in the blood stream, they circulate to influence our whole 
system. Herbs are considered food for natural medicine, vitamins, minerals and 
phytochemicals that have a remarkable history of curative effects
4
.  
 
 Pharmacognostic science, considered the mother of all the sciences, owes its 
birth to the advent on earth of the earliest man, who had no choice but to search his 
surroundings for some product to relieve his pain and cure the diseases
5
.  
 
Today the world is moving from spiritual to digital. The digitalization of 
herbal medicines, once considered spiritual, is progressing at a rapid space. There is 
global resurgence in the use of traditional systems of medicine which are based on 
drugs of natural origin
6
.   
 
Herbal medicine 
 The WHO has recently defined traditional medicine (including herbal drugs) 
as comprising therapeutic practices that have been in existence, often for hundreds of 
years, before the development and spread of modern medicine  and are still in use 
today (WHO, 1991). 
 
Why herbal medicine? 
7 
Herbal medicines have stood the test of time for their safety, efficacy, cultural 
acceptability and lesser side effects. The chemical constituents present in them are a 
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part of the physiological functions of living flora and hence they are believed to have 
better compatibility with the human body. 
 
Back ground of Traditional Herbal Medicine 
8 
 Plants, animals and the human beings have intimate biological relationships 
since remote past and have evolved along parallel lines co-operating and depending 
upon each other for existence. The primitive men during the course of their struggle 
for existence in the forest must have encountered the miseries of pains and sickness, 
sustained injuries and lived under the circumstances of abject poverty disease and 
hunger. To liberate themselves from these sufferings they should have looked towards 
their natural fellow friends- the plants. And this inevitably led to the experimentation 
through trial and error and discovery of the healing properties of plants. It must have 
begun with the “Miraculous healing effects” of leaves of some plants with they 
covered their wounds to avoid flies and dust and with the soothing and stimulating 
effect of the leaves, root and stems of some plants which they chewed to satisfy their 
hunger. Once having been realized the significance of these “Wonder Herbs” they 
started communicating about them to their fellow friends through signs and symbols.  
Undoubtedly nature has all along with the diseases, has created their cure and for 
every disease that arises on this planet, plants have a cure. Nature keeps in her green 
bag, the secret of healthy life on this earth, perhaps in the luxuriant green cover, the 
bio-diversity.  
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History of Traditional medicine in the world 
9
 
 
Archaeological discoveries of 60,000 year old Neanderthal burial grounds in 
Iraq, point to the use of plants like marsh mallow, yarrow and ground sel. Sumerians 
(4000 BC) from their cusseiform writing on clay tablets are reported to have used 
opium, liquorice, thyme, mustard and sulphur. Egyptian’s first medical text “The 
Ebers Papyrus” contains 800 recipes and 700 drugs. The Chinese pharmacopoeia, 
Pen- Sao keng Mu, is the oldest record of herbal medicine. 
 
 Theophrastus (300 BC) a botanist whose treatise ‘Inquiry Into Plants’ 
influenced both botany and medicine for centuries is called the ‘Father of 
Pharmacognosy’ (Farooqi & Sreeramu 2001). In De Materia Medica, Dioscorides 
(64-120 AD) discussed in detail the identification, collection, adulteration and 
therapeutic uses of several thousands of plants.  
 
History of traditional medicine in India  
 
 In India, the use of different parts of several medicinal plants to cure specific 
ailments has been in vogue from ancient times. The indigenous system of medicine 
namely Ayurveda, Siddha, Unani, Homeopathy have been in existence for several 
centuries. 
 
 The earliest mention of the medicinal use of plants is found in the Rig Veda 
(4500-1600 BC). In Ayurvedha, the properties of various drugs have been given in 
detail. Susruta Samhita (1000 BC) contains a comprehensive chapter on therapeutics 
and Charaka Samhita, gives a remarkable description of the Materia Medica. Later 
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during the Buddhist period, the medicinal plants were cultivated. Contacts with 
Greece and Rome, and later with Arabia and Persia, contributed to the enrichment of 
the Indian Materia Medica and a large number of vegetable and other products came 
into use for the treatment of diseases. 
 
IMPORTANCE OF HERBAL MEDICINE 
5 
Medicinal plants are used at the house hold level to improve the health of the 
family members.  
These herbs are used in the various forms.  
 Food for growth 
 Food and herb as medicine 
  
REASONS FOR THE USE OF NATURAL PRODUCTS 
6
 
They provide a number of extremely useful drugs that are difficult, if not 
impossible, to produce commercially by synthetic means. They include alkaloid of 
poppy, ergot and solanaceous.  
 Natural sources also supply basic compounds that may be modified slightly to 
render them more effective or less toxic. The numerous variations of the morphine 
molecule serve as example here.  
Utility of natural products as prototypes or models for synthetic drug 
processing physiological activities similar to the original drug. Procaine and similar 
local anesthetics are commonly cited as representatives of this category. 
Other important application is that the natural products contain compounds 
that demonstrate little or no activity themselves but which can be modified by 
chemical or biological methods to produce potent drugs not easily obtained by other 
methods.  
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APPLICATION OF HERBAL MEDICINE 
7 
 
 Herbal medicines have long history of use and better patient tolerance as well 
as acceptance 
 Medicinal plants have a renewable source, which is our only hope for 
sustainable supplies of cheaper medicines for the world growing population. 
 Availability of medicinal plants is not a problem especially in developing 
countries like India having rich agro-climatic, cultural and ethnic biodiversity  
 The cultivation and processing of medicinal herbs and herbal products is 
environmental friendly 
 Cost-effectiveness-prescription drugs cost much more money than herbal 
medicines 
 Lower side effects herbal medicines are generally a far heal their solution 
than prescription drugs due to potential harmful side effects caused by 
unpredicted body chemistry interactions. 
 Obesity is the cause of many of the health problems. Herbal medicine can 
help to reduce excess weight and regulate appetite.  
Traditional medicine vis-à-vis modern medicine 
10 
There is a difference in the mode of action of traditional herbal medicine 
(THM) and modern synthetic medicine (MSM). Whereas the latter attacks the disease 
directly and helps the patient through the destruction of the disease, the former 
approaches the patient directly, over the head of the disease and destroys it by a 
process of reinforcement or bolstering up of the patient’s body resistance and immune 
system. Also, modern medicine attacks the target blindly, thus affecting several 
INTRODUCTION  
 
Department of Pharmacognosy, COP, MMC, Chennai- Ͳ͵  Page ͹ 
 
related metabolic systems of the body including the immune system. Herbal medicine 
works selectively and gently without disturbing the other systems of the body.  
Isolation and Characterization of Active Principles 
11,12 
 The work of isolation of active principles from medicinal plants and 
characterization can be traced to the beginning of 19
th
 century. From crude drug Ma 
Huang (Ephedra spp) of China, ephedrine was isolated in 1887 and later introduced as 
drug in 1925. Likewise, from opium (Papaver somniferum), morphine was isolated in 
1804 and introduced as drug in 1818, from Cinchona spp. of Peru, quinine was 
isolated in 1820 and introduced as drug in 1825. emetine was isolated in 1894 and 
introduced as drug in 1912. 
 
  Large number of drugs from medicinal plants were discovered and introduced 
in modern pharmacopoeias during 1850-1950. Some of the important crude drugs are 
Belladonna (Atropa belladona), Cascara (Rhamnus purshiana), Digitalis (Digitalis 
purpurea), Rauwolfia (Rauwolfia serpentina). From 1950 onwards, there was 
research of ethno therapeutics in search of new drugs from higher plants and marine 
flora. During this period there was outstanding contribution of drugs from higher 
plants like reserpine, deserpidine and rescinnamine from Rauwolfia serpentina; and 
vinblastine and vincristine from Catharanthus roseus. 
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POLYCYSTIC OVARIAN DISEASE 
Polycystic ovarian syndrome or Polycystic ovarian disease (PCOS or PCOD) 
in humans is also known as the Stein - Leventhal syndrome. It is a hormonal 
endocrine disorder of child bearing age recognized as the primary cause of infertility.  
 
Polycystic ovarian disease is a heterogenous, multisystem endocrinopathy in 
women of reproductive age with the ovarian expression of various metabolic 
disturbances and a wide spectrum of clinical features such as obesity, menstrual 
abnormalities and hyperandrogenism. Women (5% - 10%) of reproductive age are 
affected by PCOD.  
Long term consequences include increased risk of endometrial cancer, type 2 
diabetes mellitus, dyslipidemia, hypertension and cardiovascular disorders. The 
etiology of PCOD is not clearly understood, but lipid imbalance, oxidative stress, 
insulin resistance and genetics are some of the contributing factors.  
 
PCOD is frequently diagnosed by gynaecologists and it is therefore important 
that there is a good understanding of the long-term implications of the diagnosis in 
order to offer a holistic approach to the disorder. PCOD is characterized by multiple 
small ovarian cysts less than 1cm, LH is raised and LH/FSH ratio is ≥2. Current 
incidence of PCOS (5-6%) is fast increasing lately due to change in lifestyle and 
stress. Amongst infertile women, about 20% infertility is attributed to anovulation 
caused by PCOD. 
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                                    Fig. 1 Normal Ovary and Polycystic Ovary 
      
 
Fig. 2 Pathological difference between Normal Ovary and Polycystic Ovarian 
Disease 
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SYMPTOMS  
Common symptoms, signs & metabolic abnormalities of PCOD 
13
  
Not all women with PCOD share the same symptoms 
1) Oligomenorrhea or amenorrhea, and / or irregular bleeding. 
2) Male pattern baldness or thining of scalp hair, Hirsutism involving face, chest, 
stomach, back, thumbs or toes.  
3) Acne vulgaris – moderate to severe (treatment resistant / cystic). 
4) Acanthesis nigricans (patches of thickened, dark brown or black skin) on the 
neck, arms, breasts or thighs. 
5) Skin tags in the armpits or neck area. 
6) Depression.  
7) Sleep apnea syndrome. 
8) Overweight or obesity, usually central. 
9) Insulin resistance glucose intolerance and type II diabetes. 
10)  Hyperlipidemia. 
11)  Nonalcoholic fatty liver disease. 
12)  High blood pressure. 
13)  Anovulation and infertility. 
14)  High risk of coronary artery disease. 
15)  Prothombotic state.  
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CAUSES 
13 - 21 
While exact cause of PCOD is unknown, doctors believe that hormonal 
imbalances and genetics play a role. Women are more likely to develop PCOD if their 
mother or sister also has the condition. Over production of the hormone androgen may 
be another contributing factor. Androgen is a male sex hormone that women’s bodies 
also produce. Women with PCOD often produce higher-than-normal levels of 
androgen. This can affect the development and release of eggs during ovulation. 
Excess insulin (a hormone that helps convert sugars and starches into energy) may 
cause high androgen levels.  
 
 
Fig. 3  Symptoms of PCOD 
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PATHOLOGY 
18,22
   
The ovaries are enlarged. Ovarian volume is increased ≥10 cm3. Stroma is 
increased. The capsule is thickened and pearly with in color. Presence of multiple 
(≥12) follicular cysts measuring about 2 – 9 mm in diameter are found crowded 
around the cortex.  
 
                        
                                         
Fig 4. Pathophysiological changes of PCOD 
 
MORPHOLOGY 
18 
The ovaries are usually twice normal size and have a smooth, grey-white outer 
cortex studded with subcortical cysts 0.5 to 1.5 cm in diameter. On histologic 
examination, there is a thickened fibrotic superficial cortex beneath which are 
innumerable follicle cysts associated with hyperplasia of the theca interna (follicular 
hyperthecosis), Corpora lutea are frequently but not invariably absent.  
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CLINICAL FEATURES 
26-29 
The pathogenesis appears to be initiated in utero or early adolescents period. 
Early adrenarche in the form of early pubertal hair and early menarche is observed in 
a few girls. Menstruation for a couple of years may be normal, but clinical features of 
PCOD develop early with Oligomenorrhoea (87%) or with a short period of am 
enorrhoea (26%) followed by prolonged or heavy periods (a common compliant in a 
majority of cases). Dysmenorrhoea is absent. 
In the reproductive years, infertility accounts for about 20% cases. This is due 
to anovulatory cycles. During pregnancy, if the women conceives, carbohydrate 
intolerance, diabetes and hypertension may develop. Pregnancy loss occurs in 20-
30%. Hyperandrogenism appears in the form of acne (30%) and hirsutism. Facial hair 
appears over the upper lip, chin, breasts and thighs. Baldness is sometimes noted, but 
virilism does not develop. 
Family history of diabetes and hypertension should be asked. Excessive 
exercise, history of tuberculosis and thyroid are important in menstrual disorder. 
 
Table 1 :  FEATURES OF POLYCYSTIC OVARIAN DISEASE
13 
 
MECHANISM MANIFESTATIONS 
Pituitary dysfunction 
High serum LH 
High serum prolactin. 
Anovulatory Menstrual cycles 
Oligomenorrhoea, Secondary amenorrhoea, 
Cystic ovaries, Infertility. 
Androgen excess Hirsutism, Acne 
Obesity Hyperglycemia, Elevated androgen 
Insulin resistance Dyslipidaemia, Hypertension 
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EXAMINATION 
30-39 
 Obesity, especially waistline. Waist over hip ratio >0.85 is abnormal; 50% 
women are obese. 
 Body mass index between 25 and 30 – overweight; and above 30 – 
obesity. 
 Thyroid enlargement. 
 Hirsutism and acne.  
 Hyperinsulinaemia which may manifest as acanthosis nigra (5%) over the 
nape of the neck, axilla and below the breasts; 75% obese women reveal 
hyperinsulinaemia. 
 Blood pressure in obese women.  
Pelvic findings are normal, and it is not common to palpate the enlarged ovaries.  
For the diagnosis of PCOD, the Rotterdam criteria (2003) suggests that at least two 
out of three criteria should be present. These criteria are:  
 Oligo / Amenorrhoea, Anovulation, Infertility 
 Hirsutism – Acne  
 Ultrasound findings. 
DIAGNOSIS 
31-39
  
The diagnosis of PCOD is traditionally made on clinical history and endocrine 
assessment and there is now an ongoing discussion on the merits of classifying 
women with the disorders on the basis of endocrine and metabolic criteria versus 
ovarian Ultrasound based criteria. In many cases, PCOD may be identified solely on 
the ultrasonographic morphology of the ovaries, however the metabolic disorder may 
be present in a women with normal-appearing ovaries, and women with ovaries 
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profoundly suggestive of PCOD on ultrasound examination may appear to be 
phenotypically normal.  
There is no specific test for PCOD but your doctor will consider your symptoms and 
usually complete a physical examination, blood tests and a transvaginal ultrasound. 
Physical examination 
The doctor will ask numerous questions about your menstrual cycle, 
symptoms, weight and examine you for physical signs of PCOD, e.g. – acne, excess 
hair growth and darkened skin.  
Blood tests  
Blood may be tested for high cholesterol, blood sugar levels (insulin 
resistance) and for changes in LH (luteinizing hormone) or FSH (follicle stimulating 
hormone).   
Transvaginal ultrasound  
A long term slender probe is inserted into the vagina to determine the presence 
of ovarian cysts or enlarged ovaries and also to examine the reproductive organs or 
any irregularities. If would prefer not to have a vaginal scan, the doctor may conduct 
an ultrasound of  abdomen – done externally while you have a full bladder.  
 
INVESTIGATIONS 
35-39 
Ultrasound is diagnostic of PCOD 
¾ It confirms the enlarged ovaries, their size and increased stroma. Ovarian 
volume will be more than 10 mm. 
¾ It shows 12 or more small follicles each of 2-9 mm in size placed peripherally. 
¾ It rules out ovarian tumor. 
¾ It shows endometrial hyperplasia if present. 
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¾ Hormonal study mentioned earlier is not performed routinely, but specific 
hormonal studies are undertaken in a women as and when required. All 
hormonal studies are not needed as a routine.  
¾ Thyroid function tests in obese woman. 
¾ Laproscopy is reserved for therapeutic purpose, now that the diagnosis can be 
confirm ultrasound findings. Laproscopy reveals enlarged bilateral ovarian 
cysts. 
 
   
  Fig 5. Ultrasound examination of PCOD 
PHARMACOTHERAPY  
This includes many agents which may be beneficial in addressing the 
individual components, however the most popular theraphy now a days is insulin 
sensitizers, as this is supposed to break the root cause of syndrome, the insulin 
resistance. 
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Insulin sensitizers  
Metformin  
A biguanide that primarily inhibits hepatic gluconeogenesisand lipogenesis 
and also enhances peripheral glucose uptake, at doses of 1000 – 2500 mg daily, 
appears valuable in increasing menstrual cyclicity and pregnancy rate. Metformin is 
preferred given its long history of safe use in PCOD.  
Thiazolidinediones are associated with weight gain, fluid retention and heart failure. 
Clomiphene citrate  
This is an oral oestrogen antagonist that raises circulating concentrations of 
FSH and induces follicular ultrasound examination and luteal progesterone level. 
Combination of clomiphene citrate and metformin has been used successfully in a 
cubset for ovulation induction. Clomiphene with dexamethasone improves fertility 
rate.   
Gonadotrophin treatment  
Patients start on low dose recombinant FSH administered subcutaneously. 
Human chronic gonadotrophin is given when one follicle reaches 16 – 20 mm in size, 
multiple gonadotrophin cycles may be required to achieve pregnancy. 
In – vitro fertilization  
Ovulation induction by a skilled reproductive endocrinologist is preferable to 
in – vitro fertilization because of the risks of hyper – stimulation and multiparity with 
the latter procedures. As clomiphene citrate rapidly blocks steroid negative feedback 
with 10% multiparity, whereas metformin gradually reduces hyperinsulinemia with 
low multiparity. Clomiphene citrate may be preferable when time to conceive is 
essential. 
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Surgical treatment  
Ovarian wedge resection is the surgical removal of part of an ovary. This is 
done to help regulate menstrual cycles and start normal ovulation. It is rarely used 
now because of the possibility of damaging the ovary and creating scar tissue. 
Laproscopic ovarian drilling is a surgical treatment that can trigger ovulation 
in women who have PCOD and who have not responded to weight loss and fertility 
medicine. Electrocautery or a laser is used to destroy portions of the ovaries. 
                                 
 
Fig. 6 Ovarian drilling 
 
RISK FACTORS OF PCOD 
37-38 
Cardiovascular Disease  
They should hence be regularly monitored and advised to consume less fat and 
cholesterol. PCOD is characterized by endothelial dysfunction and resistance to the 
vasodilating action of insulin. An increased risk of myocardial infarction in PCOD 
women than age – matched controls has also been reported.  
Obesity  
Obesity is also a feature observed and estimated to effects 50% of PCOD 
women, classically presented in patients with upper body obesity which has been 
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associated with menstrual disturbances. It amplifies biochemical and clinical 
abnormalities of PCOD. Previously obesity was thought to be the cause of PCOD but 
now understood as a modifier of the condition. 
Infertility 
Infertility is the complicating feature of PCOD is the effects it has on 
ovulation and fertility with >75% of women with anovulation infertility and treatment 
is based upon the patient’s characteristics.  
Complication of PCOD  
Endometrial cancer  
Recent interest in the long term risks of PCOD has also focused on its possible 
associations with endometrial cancer. Prolonged anovulation which characterizes the 
syndrome is considered to be the main mechanism responsible for continual 
unopposed secretion of estrogens and consequent increased risk of endometrial 
carcinoma. The known factors which increase the risk of developing endometrial 
cancer are obesity, long term use of unopposed oestrogens, nulliparity, infertility, 
hypertension and diabetes.   
Complications in pregnancy  
Women with PCOD have a greater risk of complications viz. Gestational 
diabetes, pre – eclampsia, pre – term labor, small for gestational age, pregnancy 
induced hypertension, spontaneous abortions.  
Sleep Apnoea  
Women with PCOD have increased Sleep Disordered Breathing (SDB) and 
daytime sleepiness. Depression there was a higher prevalence of depression in PCOD 
patients associated with higher body mass index and greater insulin resistance. 
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NEED FOR NATURAL SOURCES AS POLYCYSTIC OVARIAN DISEASE  
       
Natural products from plant, animal and minerals have been the basis of the 
treatment of human disease. Today estimate suggests that about 80% of people in 
developing countries still rely on traditional medicine based largely on species of 
plants and animals for their primary health care.  
The use of herbal medicine is becoming popular due to toxicity and side 
effects of allopathic medicines. Medicinal plants play an important role in the 
development of potent therapeutic agents. There are over 1.5 million practitioners of 
traditional medicinal system using medicinal plants in preventive, promotional and 
curative applications. 
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Table – 2  MEDICINAL PLANTS USED FOR POLYCYSTIC OVARIAN 
DISEASE
41 
S.No 
Botanical 
name 
Part 
used 
Family 
Chemical 
constituent 
Medicinal uses 
1. 
Aloe 
barbadensis 
Aloe 
juice 
Liliaceae Aloin 
Dysmenorrhoea, 
menstrual 
suppressions. 
2. 
Curcuma 
longa 
Rhizome Zingiberaceae Cucumin 
Decrease the 
cholesterol level. 
3. 
Erythrina 
variegata 
Leaves Fabaceae Steroids Emmenagogue. 
4. 
Astragalus 
officinalis 
Flower Fabaceae Polysaccharides Insulin resistance 
5. 
Cinnamomum 
zylanicum 
Bark Lauraceae Essential oil 
Decrease insulin 
resistance. 
6. Saraca indica 
Leaves 
& 
Flower 
Fabaceae Tannin Uterine tonic 
7. 
Glycyrrhiza 
glabra 
Root Leguminosae 
Glycyrrhizic 
acid 
Reduce serum 
testerone. 
8. 
Lepidium 
sativum 
Seeds Curciferaceae 
Oestrogenic   
activity 
Emmenagogue. 
9. 
Linum 
usitatissiumum 
Seeds Linaceae 
Chlorogenic 
acid 
Reduce the 
hirsutism 
10. 
Tribulus 
terrestris 
Fruit Zygophyllaceae
Alkaloids, fixed 
oil 
Hypoglycemic, 
hypolipidemic, 
diuretic. 
 
Literature reveals that the above mentioned plants are used in Polycystic 
Ovarian Disease. The plant Erythrina variegata Linn., claimed to be useful for 
Polycystic Ovarian Disease has not been evaluated scientifically.  
REVIEW OF LITERATURE  
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REVIEW OF LITERATURE 
Pharmacognostical Review  
1) Verma et al (2016) Phyto – Pharmacognostical investigations and 
evaluation of anti – inflammatory and sedative hypnotic activity of the 
leaves of Erythrina variegata lam
41
. 
2) Ramila Devi et al (2011) characteristics of Pharmacognostical 
significance of Erythrina variegata var Bark
42
. 
3) Kumar et al (2010) Erythrina variegata linn: A review on Morphology, 
Phytochemistry and Pharmacological aspects
43
. 
 
Phytochemical Review  
4) Subramanian et al (2016) Phytochemical screening and HPTLC 
Fingerprinting analysis of ethanolic extract of Erythrina variegata 
L.flowers
44
. 
5) Valli et al (2015) Erythrina variegata leaves extract Assisted Synthesis of 
Titanium Dioxide Nanoparticles in an Ecofriendly Approach
45
. 
6) Valli et al (2015) Molecular properties and bio – activity of alkaloids in 
Erythrina vaiegata leaves to find lead compound
46
.  
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Pharmacological review  
7) Jagdish et al (2015) reported the Hypoglycemic and Hypolipidemic 
activity of Root extracts of Erythrina variegata in Alloxan induced  
diabetic rats
47
. 
8) Mangathayaru et al (2014) reported the Estrogenic effect of Erythrina 
variegata L. in perpubertal female rats
48
. 
9) Murugalakshmi et al (2014) reported the Analgesic and Anti – 
inflammatory activities of Erythrina variegata leaves extracts
49
. 
10)  Sahoo et al (2012) reported the In – vitro  analysis of antimicrobial 
activity of stem extracts of Erythrina variegata L : A useful medicinal 
plant
50
 . 
11)  Baskar et al (2010) reported the Anti – cancer activity of methanol 
extract of root bark of Eytrina variegata Linn
51
. 
12) Ajay kumar et al (2010) In – vitro antioxidants and anti – inflammatory 
activities of Erythrina variegata bark
52
. 
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ETHNOBOTANICAL SURVEY 
Ethnobotanical Survey of Erythrina variegata Linn., 
 PLANT PROFILE 
53-64
  
 Plant name : Erythrina variegata Linn.,  
 Common name : Indian coral tree  
 Synonym : Eryhtrina indica  
 Family : Fabaceae  
VERNACULAR NAMES 
59-65
  
Tamil  : Kaliyana Murungai 
English name : Indian coral tree, Moochy wood tree.  
Sanskrit : Mimbataru, Manalia.   
Bengali : Palita-madar, Palidhar.  
Hindi : Ferrud, Mandar, Pangra.   
Telugu : Barijiamu , Modugo, Badchipa-chettu.  
Gujarati : Panarawas, Pararoo.   
Malayalam : Mooloomogrikah.  
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TAXONOMIC CLASSIFICATION 
53-54 
Botanical name : variegata 
Family : Fabaceae 
Sub family : Papilionaceae 
Kingdom : Plantae  
Divisions : Mangoliophyta  
Classs : Mangnolipsida – Dicotyledons 
Genus : Erythrina L- coral tree  
 Species : Erythrina variegta L.   
 
Fig 7. Erythrina variegata Linn., tree 
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Table 3. Erythrina variegata Linn., Leaves 
 
                 Size of the matured  leaves 
 
            Size of the young leaves 
  
 
                              Dorsal surface 
                   
                     Ventral surface 
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Table 4. Habitat and Height of the plant 
 
                  Habitat of the plant 
 
                      Height of the plant 
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PLANT DESCRIPTION 
53
 
Erythrina variegata Linn., belongs to the family Fabaceae commonly known as the 
‘Indian coral tree’ in Asia or ‘tropical coral’ in the Pacificis an important multipurpose tree 
species and thrives well in arid and semiarid region. Erythrina variegata Linn., is found in 
many tropical and subtropical regions. 
DESCRIPTION 
54 
Erythrina variegata Linn.,  is a medium – sized, spiny, deciduous tree normally 
growing to   6 – 9 m (occasionally 28 m) tall and 60cm.  
Table 5. Plant  Description 
S.NO PART DIAGRAM FEATURES 
1 LEAVES 
 
           
        Leaves trifoliate, alternate, bright 
emerald – green, on long petioles  6 – 15 
cm, rachis 5 – 30 cm long, prickly; 
leaflets smooth, shiny, broader than long, 
8– 20 by 5–15cm, ovate to acuminate 
with an obtusely pointed end.  
2 BARK 
 
     
        Bark is smooth and green when 
young, exfoliating in papery flakes, 
becoming thick, corky and deeply 
fissured with age. 
3 FLOWER 
  
     Flowers in bright pink to scarlet red, 
erect terminal racemes 15 – 20 cm long; 
stamens slightly protruding from the 
flower.  
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4 STEM 
         
         Erythrina variegata is a compact 
shrub with prickly stems. 
 
5 
FRUIT 
 
         
      Fruit a cylindrical torulose pod, 
green, turning black and wrinkly as they 
ripen, thin – walled and constricted 
around the seeds 
6 SEED 
       
     Seeds are 1 – 8 smooth, oblong, dark 
red to almost black seeds per pod 
 
ETHNOBOTANICAL USES 
40-51 
Different parts of the plant have been used in the traditional system of medicine as a nervine 
sedative, collyrium in opthalmia, anti-asthmatic, antiepileptic, antiseptic and as an astringent.  
LEAVES  
 They are applied externally for depressing veneral buboes and for relieving pain in 
joints
,
.  
 The leaves are laxative, diuretic, anthelnmintic, galactagogue, emmenagogue.   
 The fresh juice of the leaves is used for the relief of ear ache and as anodyne in tooth-
ache. 
 The juice is also used for killing worms in sores. The paste of the leaf is applied 
externally to relieve pain in hernia and hydrocele.  
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 The paste of leaf is applied for ulcers.  
 Leaf juice said to cured long - standing dysmenorrhoea and also removed sterility in 
fatty women by gradually reducing fat and produce natural menstrual flow, if the 
medicine is being continued for two or three months  
 
BARK  
 Bark is boiled for preparation of tears and baths for skin diseases and impetigo.  
 Cooked rice soaked in steam bark extract for a day and then made into paste is given 
internally in menorrhagia. 
 A decoction of the bark scrapings with lemon juice for the treatment of infertility. The 
juice of the bark and that of Moringa oleifera lam mixed with common salt is given 
internally in acute conditions of stomachache.  
 Haemagglutinating activity has been reported in seed extract which specifically 
inhibits galactose and lactose.  
SEEDS 
 The seed trypsin inhibitors inhibit plasmin involved in the blood coagulation and 
fibrinolytic system.   
 The root extracts exhibits antimicrobial activity in vitro against Staphylococcus 
aureus and Mycobacterium megmatis.  
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RATIONALE FOR SELECTION  
 
 The plant Erythrnina variegatea Linn., belonging to the family Fabaceae was 
selected for the present work.  
 The Ethnomedicinal uses were a nervine sedative, collyrium in opthalmia, 
anti-asthmatic, antiepileptic, antiseptic, astringent, toothache, emmenagogue 
and galactagogue. Erythrina variegata Linn. is an adulterant to the ayurvedic 
drug Rohitaka.    
 The Polycystic Ovarian Disease activity was not scientifically validated. 
 So the leaves of the plant Erythrina variegata Linn., was selected for 
evaluation of Polycystic Ovarian Disease activity.  
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    AIM AND OBJECTIVES  
 To objective of the study is to explore the Phamacognostical, Phytochemical 
and Pharmacological profile on the leaves of Erythrina variegata Linn.,  
 Collection and Authentication of the plant specimen.  
 Establishing Pharmacognostical profile of the plant. 
 Extraction of plant material by using, Soxhlet apparatus with solvents of 
increasing polarity such as Petroleum ether > Chloroform > Ethyl acetate > 
Ethanol and Aqueous (cold maceration).  
 Phytochemical screening and determination of bioactive constituents. 
 Evaluation of Polycystic Ovarian Disease activity by In – vitro and In – vivo 
models.  
 Isolation of compound using Column Chromatography. 
 Survey of Polycystic Ovarian Disease. 
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PLAN OF WORK 
PHARMACOGNOSTICAL STUDIES 
 Macroscopical studies 
 Microscopical studies 
 Powder Microscopy  
 Quantitative Microscopy- Leaf constants. 
 Quantitative Microscopy -Linear Measurements of Calcium Oxalate Crystals  
 Histo-chemical studies 
 Determination of Physico-chemical constants.  
¾  Ash values 
` Total ash value 
` Acid insoluble ash value 
` Water soluble ash value 
` Sulphated ash value 
¾ Extractive values 
` Alcohol soluble extractive value 
` Water soluble extractive value 
` Ether soluble extractive value 
¾ Determination of crude fiber content 
¾ Determination of Loss on Drying 
¾ Determination of Swelling index 
¾ Determination of Foaming index 
¾ Determination of Volatile oil content 
 Qualitative and Quantitative Estimation of Heavy metals and Inorganic 
element 
PLAN OF WORK 
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 II. PHYTOCHEMICAL STUDIES 
 Preparation of Extracts 
 Preliminary Phytochemical screening of extracts  
 Quantitative Estimation of Phytoconstituents 
 Fluorescence analysis of Plant powder and extracts 
 Thin Layer Chromatography.  
 High Performance Thin Layer Chromatography-Finger Print profile.  
 
III. SELECTION OF ACTIVE EXTRACT 
 In – vitro DPPH assay 
 In – vitro Hydrogen Peroxide Scavenging Assay. 
 
IV. PHARMACOLOGICAL STUDIES 
 Acute toxicity studies 
 In vivo Letrazole induced Polycystic Ovarian Disease  
¾ Body weight 
¾ Food intake 
¾ Vaginal exfolitative cytology  
¾ Blood Glucose level 
¾ Lipid profile  
¾ Reproductive organ weight (Uterus and Ovary). 
¾ Histopathological study of uterus and ovary   
 
IV. ISOLATION OF COMPOUND USING COLUMN CHROMATOGRAPHY 
  Infra red spectroscopy  
  Gas chromatography-Mass spectroscopy studies 
 V. SURVEY OF POLYCYSTIC OVARIAN DISEASE  
MATERIALS AND METHODS 
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MATERIALS AND METHODS 
 
PHARMACOGNOSTICAL STUDIES 
Collection of Plant Material  
The leaves of Erythrina variegata Linn., was collected from Karur district 
Pillapalayam village, Tamilnadu in August – 2016.   
Identification and Authentication of Plant Material 
The collected specimens was botanically identified and authenticated by Dr. 
R. Jayaraman Ph.D., Director, Institute of Herbal Botany Plant Anatomy Research 
Centre, West Tambaram, Chennai-45. It was identified as Erythrina variegata linn 
Fabaceae family.  
MACROSCOPY  
Fresh leaf of Erythrina variegata of were collected and different organoleptic 
features viz shape, size, colour, type, odour, taste were observed. These parameters 
are considered useful in the qualitative control of the crude drug and evaluated as per 
standard WHO guidelines. 
 
MICROSCOPY 
65-79 
Staining method  
Fixation of plant material  
The sample or leaves was cut fixed in FAA solution (Formalin 5ml + Acetic acid 
5ml + 90ml of 70% Ethanol). The specimen was dehydrated after 24 hours of fixing. The 
seeds were graded with series of tertiary butyl alcohol, as per the standard method.  
Infiltration of the specimen  
MATERIALS AND METHODS 
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It was carried out by gradual addition of 58 – 60
0
 C of melting pointed paraffin 
wax until Tertiary butyl alcohol (TBA) solution attained super saturation. The specimens 
were cast into paraffin blocks. 
Sectioning  
The paraffin embedded specimens were  sectioned with the help of Rotary 
Microtome. The thickness of the sections was 10 – 12µ. Dewaxing of the sections were 
done by customary procedures. The sections were stained Toludine blue. Since toludine 
blue is a polychromatic stain, the sections were stained as per the method published by 
O’Brein et al. The staining results were remarkably good. The dye rendered pink colour 
to the cellulose walls, blue to the lignified cells, dark green to subrein, violet to mucilage 
and blue to the protein bodies. Whenever necessary sections were also stained with 
safranin, fast green and iodine for starch.    
 
PHOTO MICROGRAPHS  
Microscopic descriptions of tissues were supplemented with photo micrographs 
whenever necessary. Photographs of different magnifications were taken with Nikon lap 
photo 2 microscopic units. For normal observations bright field was used.  
For the study of crystals and lignified cells, polarized light was employed. Since, these 
structures have birefringent property under polarized light they appear bright against dark 
background. Descriptive terms of the anatomical features are as given in the standard 
anatomy books.   
 
POWDER MICROSCOPY  
Shade dried leaf of Erythrina variegata were powdered well, then the powder 
was passed through sieve no.60 and used or powder analysis and organoleptic 
characters such as nature, colour, odour and taste were studied. Powder analysis using 
MATERIALS AND METHODS 
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various staining reagents viz 1% phloroglucinol in 90% ethanol, conc Hcl and N/50 
iodine. Slide were observed under the microscope. 
   
QUANTITATIVE MICROSCOPY 
81 
LEAF CONSTANT: 
DETERMINATION OF STOMATAL NUMBER AND STOMATAL INDEX  
Stomatal number is the number of stomata per sq.mm of epidermis of the leaf. 
Clear the piece of the leaf (middle part) by boiling with potassium hydroxide solution or 
alternatively with chlorinated soda. Peel out upper and lower epidermis separately by 
means of forceps. Keep it on slide and mount in glycerin water. Arrange a camera lucida 
and drawing board for making the drawing to scale. Draw a square of 1mm by means of 
stage micrometer. Place the slide with cleared leaf (epidermis) on the stage. Trace the 
epidermis cell and stomata. Count the number of stomata, also the number epidermal cells 
in each field. Calculate the stomatal index and stomatal number. Determine the values for 
upper and lower surface (epidermis) separately. 
 
DETERMINATION OF VEIN ISLET NUMBER AND VEINLET TERMINATION 
NUMBER: 
For studying the venation pattern, leaf  was cleared with 5% Sodium 
hydroxide solution and epidermal peeling by partial maceration employing Jeffrey’s 
maceration were prepared. Glycerin mounted on temporary preparations were made 
for macerated materials and used for the study of vein islet number and vein 
termination number. 
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Linear Measurements: Measurement of Calcium oxalate Crystals 
            Little quantity of powdered drug was cleared with 5% caustic soda and 
transferred to a watch glass. The calcium oxalate crystals were stained using 
phloroglucinol on a glass slide and mounted in glycerin, observed under low power. 
The intact stained calcium oxalate were focused and the entire length and width of the 
calcium oxalate crystals was measured by rotating the scale of eye piece micrometers. 
Each value was multiplied by the calibration factor. Minimum, average and maximum 
measurements of 25 observations were taken. 
 
HISTOCHEMICAL STUDIES
 82-83  
Portions of fresh fruit peels of the plant of Erythrina variegata Linn., were 
used. The peels were soaked in water before taking the sections. The sections were 
stained using specific reagents ( N/50 iodine, dilute ferric chloride, phloroglucinol and 
con.hydrochloric acid, picric acid, ortho toludine blue and dragendroff reagent) to 
observe and locate starch, lignin, tannin, protein, flavanoid and alkaloid respectively 
as per the protocols. The stained sections were then washed in water to remove the 
excess stain and observed under a microscope. 
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PHYSIO-CHEMICAL CONSTANTS 
84 – 86  
 Shade dried powdered plant materials of the fruits of Erythrina variegata 
Linn.,  was used for the determination of the physio chemical constants in accordance 
with the WHO guidelines. 
DETRMINATION OF ASH VALUES 
 Ash values are helpful in determining the quality and purity of a crude drug in 
the powdered form. The residue remaining after incarnation is the ash content of the 
drug, which simply represents inorganic salts, naturally occurring drug or adhering to 
it or delibility added to it, as a form of adulteration. 
 Ash value of a crude drug is defined as the inorganic residue remaining after 
incineration, which complies of inorganic salts, naturally occurring in drug or 
adhering to it or deliberately added to it as a form of adulteration. Hence it is used for 
the determination of the quality and purity of the crude drug in the powdered form.  
TOTAL ASH: 
 Total ash method is designed to measure the total amount of material 
remaining after ignition.  They include both physiological ash which is derived from 
plant tissue itself and non-physiological ash which is the residue of extraneous matter 
adhering to the plant surface. 
Procedure:  
 Silica crucible was heated to red hot for 30 minutes and cooled in the 
desiccators Incinerate about 2 to 3 g accurately weighed, of the ground drug in a 
tarred silica dish at a temperature not exceeding 450
0
c until the sample is free from 
carbon, cooled in desiccators and weighed. The ash obtained was weighed. The 
percentage of total ash was calculated.  
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WATER SOLUBLE ASH: 
The difference in weight between the total ash and the residue after treatment 
of the total ash in water. 
Procedure: 
 Total ash obtained is boiled for 5 minutes with 25 ml of water, insoluble 
matter were collected in a ashless filter paper, washed with hot water and ignite for 15 
min at a temperature not exceeding 450
0
.  Subtract the weight of this residue in mg 
from the weight of total ash. Calculate the content of water-soluble ash in mg per 
gram of air-dried material.  
   Water soluble ash =  Weight of residue obtained  X 100 
      Weight of the sample taken  
ACID INSOLUBLE ASH: 
 The residue obtained after boiling the total ash with dilute hydrochloric acid, 
the remaining insoluble matters are ignited and measured. This measures the amount 
of silica present, especially as sand and siliceous earth.  
Procedure:  
 To the crucible containing total ash of the sample, 25 ml of dilute hydrochloric 
acid is added. The insoluble matter is collected on an ashless filter paper (Whatman 
41) and washed with hot water until the filtrate is neutral.  Filter paper containing the 
insoluble matter to the original crucible, dry on hot plate and ignite to constant 
weight. Allow the residue to cool in a suitable desiccators for 30 minutes and weighed 
without delay. Content of acid-insoluble ash with reference to the air dried drug is 
calculated. 
  Acid insoluble ash = Weight of the residue obtained    x 100 
               Weight of the sample taken  
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SULPHATED ASH 
 Sulphated ash test is used to measure the amount of residual substance not 
volatilized from a sample. These test are usually used to determine the content of 
inorganic substance.  
Procedure:  
 Silica crucible are heated to redness for 10 minutes, allowed to cool in a 
desiccator and weigh. 2 g of sample were accurately weighed, ignited gently then 
thoroughly chared. Cool, moistened the residue with 1 ml of sulphuric acid, heat 
gently until the white fumes are no longer evolved and ignite at 800 ± 25
o
 until all 
black particles have disappeared. Crucible are allowed to cool,  add few drops of 
sulphuric acid and heat. Ignite as before, allow to cool and weigh. This process is 
repeated until two successive weighing differ by more than 0.5 mg.  
 Sulphated ash = Weight of the residue obtained  x 100 
   Weight of the sample taken 
DETERMINATION OF EXTRACTIVE VALUES: 
Extractive values are useful for the evaluation of phyto constituents especially 
when the constituents of a drug cannot be readily estimated by any other means. 
Further these values indicate the nature of the active constituents present in a crude 
drug. 
Determination of water soluble extractive 
5gm of air dried coarsely powdered sample was weighed and macerated with 
100ml of chloroform water (95ml distilled water and 5ml chloroform) in a closed 
flask for 24 hours. It was shaken frequently for six hours and allowed to stand for rest 
eighteen hours. It was then filtered rapidly, taking precautions against loss of solvent 
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and 25ml of the filtrate was evaporated to dryness in a tarred flat bottomed shallow 
dish and was dried at 105°C for 1 hour in the hot air oven and cooled in desiccators 
for 30min and weighed. The process was repeated till a constant weight was obtained; 
the percentage of water soluble extractive value was calculated with reference to the 
air dried drug. 
    Water soluble extractive value =  Weight of the dried extract   x   100 
 Weight of the sample taken 
 
Determination of alcohol soluble extractive 
5gm of the coarsely powdered sample was weighed and macerated with 100ml 
90% ethanol in a closed flask for 24 hours. It was shaken frequently for six hours and 
allowed to stand for eighteen hours. It was then filtered rapidly, taking precautions 
against loss of solvent and 25ml of the filtrate was evaporated to dryness in a tarred 
flat bottomed shallow dish. It was dried at 105°C for 1hour in a hot air oven. The dish 
was cooled in desiccator and weighed. The process was repeated till the constant 
weight was obtained. The percentage of alcohol soluble extractive value with 
reference to the air dried drug was calculated. 
      Alcohol soluble extractive   =  Weight of the dried extract  x 100 
 Weight of the sample taken  
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Determination of ether soluble extractive 
2gm of powdered sample was accurately weighed and extracted with 
anhydrous diethyl ether in a continuous extractive apparatus for 20hours. The ether 
solution was transferred to tarred porcelain dish and evaporated spontaneously, dried 
over phosphorous pent oxide for 18hours and the total ether extract was weighed. The 
extract was heated gradually and dried at 105°C to constant weight. The loss in 
weight represents the volatile portion of the extract. 
 
 Volatile ether soluble extractive  =  Weight of the dried extract x  100 
      Weight of the sample taken 
 
LOSS ON DRYING 
10 g of the sample substances (without preliminary drying) was taken in a 
tarred evaporating dish.  Use of high speed mill in preparing the samples are avoided. 
The sample in the tarred evaporating dish were placed in the drying chamber (105°C) 
for 5 hours and weigh. Drying and weighing is continued every one hour interval until 
the difference between the two successive weight is not more than 0.25 percent. 
Constant weight is reached when the two consecutive weighing after drying for 30 
minutes and cooling for 30 minutes in a desiccators, show not more than 0.001 g 
difference. Percentage moisture content is compared with respect to the air dried 
sample. 
 % Moisture content =  Final weight of the sample X  100 
     Initial weight of the sample 
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DETERMINATION OF FOAMING INDEX 
1gm of the coarsely powdered drug was weighed and transferred to 500ml 
conical flask containing 100ml boiling water. The flask was maintained at 
temperature 80-90°C for about 30min. It was then cooled and filtered into a 
volumetric flask and sufficient water was added through the filtrate to make up the 
volume to 100ml. The decoction was poured into 10 stopper test tube (height 16cm, 
diameter 16mm) in successive portions of 1ml, 2ml, 3ml, 4ml up to 10ml and the 
volume of the liquid in each tube was adjusted with water to 10ml. The tubes were 
stoppered and shaked in a length wise motion for 15 seconds, two shakes per second. 
Allowed to stand for 15min and the height of the foam was measured. The results are 
assessed as follows. 
If the height of the foam in every tube is less than 1cm, the foaming index is 
less than   100. If a height of 1cm is measured in any tube, the volume of the plant 
material decoction in the tube (a) is used to determine the index. If this tube is the first 
or second tube in a series, prepare an intermediate dilution in a similar manner to 
obtain a more precise result. 
If the height of the foam is more than 1cm in every tube, the foaming index is 
over 1000. In this case repeat the determination using a new series of dilution of the 
decoction in order to obtain a result. Calculate the foaming index using the following 
formula: 
                                      Foaming index = 1000/a 
      Where, a = the volume in ml of the decoction used for preparing the dilution in 
the tube where foaming to a height of 1cm is observed. 
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DETERMINATION OF SWELLING INDEX  
The swelling index is the volume in ml occupied by the swelling of 1gm of 
plant material under specified conditions. A specified quantity of the plant material 
were previously reduced to the required fineness was accurately weighed and 
transferred into a 25ml glass stoppered measuring cylinder. The internal diameter of 
the cylinder should be about 16mm, the length of the graduated portion about 125mm, 
marked in 0.2ml divisions from 0 to 25ml in an upward direction. Unless otherwise 
indicated in the test procedure, add 25ml of water and shake the mixture thoroughly 
every 10min for 1hour, allowed to stand for 3 hours at room temperature. The volume 
in ml occupied by the plant material was measured including any sticky mucilage. 
Calculate the mean value of the individual determination, related to 1gm of plant 
material. 
 
DETERMINATION OF VOLATILE OIL IN THE DRUG: 
 Determination of the volatile oil in a sample is done by distilling the drug with 
a mixture of water and glycerine, collecting the distillate in a graduated  tube in which 
the aqueous portion is automatically separated and returned to the flask and the 
volume of oil collected is measured.  
 The content of the oil is expressed as percentage v/w.  
 It is performed in the Clevenger’s apparatus.  
Procedure:  
 Weighed amount of sample is distilled with the 75 ml of glycerine and 175 ml 
of water in the one litre distilling flask with few pieces of earthen ware and one filter 
paper 15 cm cut into small head. Condenser is placed above the flask and water is 
allowed to run through the condenser. Heating is discontinued after 3 to 4 hours. 
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Volume of oil collected is read in the graduated tube. The measured yield of volatile 
oil is taken to be the content of volatile oil in the drug. 
Percentage of volatile content  =  Amount of volatile oil obtained      X 100 
                   Weight of peel  
QUALITATIVE AND QUANTITATIVE ESTIMATION OF HEAVY METALS 
AND INORGANIC ELEMENTS
 87 
Plant minerals play a vital role in metabolism. Presence of elements vary with 
the soil, climate conditions etc. There are essential and non essential elements which 
may be beneficial or harmful to living things. Non essential elements like lead, 
arsenic, cyanide, chromium, cadmium, aluminium, silver bring about toxic effects 
resulting in intoxification. Hence, qualitative and quantitative estimation of inorganic 
elements in the plant Citrus maxima. (J. Burm.) Merr.  were carried out. 
 
QUALITATIVE ANALYSIS OF INORGANIC ELEMENTS AND HEAVY 
METALS  
To the ash of the drug material 50%v/v hydrochloric acid was added and kept 
for 1 hour. It was filtered and the filtrate was used for the following tests. 
Aluminium: White gelatinous precipitate of aluminium hydroxide is formed on 
addition of ammonia solution. It is slightly soluble in excess of the reagent. The 
precipitate dissolves readily in strong acid and base, but after boiling it becomes 
insoluble.   
Chlorides: Chlorides, when treated with silver nitrate solution, yield a white crude 
precipitate which is insoluble in nitric acid, but soluble after being well washed with 
water, in diluted ammonia, from which it is re precipitated by the addition of nitric 
acid. 
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Calcium: Solution of calcium salts, when treated with ammonium carbonate solution, 
yield a white precipitate after boiling and cooling the mixture (it is insoluble in 
ammonium chloride solution). 
 
Iron: Solution of ferric salts, when treated with potassium ferrocyanide solution, 
yields an intense blue precipitate which is insoluble in dilute HCL. 
Borate: The mixture obtained by the addition of sulpuric acid and alcohol (95%) to a 
borate when ignited, burns with flame tinged with green. 
Potassium: Moderately strong potassium salts, which have been previously ignited to 
remove ammonium salts, when treated with perchloric acid (60%) yield a white 
crystalline precipitate. 
Carbonate: Carbonate, when treated with dilute acid effervescence, liberating carbon 
dioxide which is colourless and produces a white precipitate in calcium hydroxide 
solution. 
Sulphates: Solution of sulphates, when treated with lead acetate solution yields a 
white precipitate which is insoluble in ammonium acetate solution and in sodium 
hydroxide. 
Silver: Solution of silver salts, when treated with potassium iodide solution yield a 
cream coloured precipitate which is insoluble in dilute ammonia solution and in nitric 
acid. 
Nitrate: With solution of ferrous sulphate no brown colour was observed but if 
sulphuric acid is added (slow from the side of the test tube), a brown colour is 
produced at the junction of two liquids, indicating the presence of nitrates. 
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QUANTITATIVE ESTIMATION OF INORGANIC ELEMENTS
 88
:  
Inductive coupled plasma-Optical emission spectroscopy (ICP-OES)  
It is an excellent multi-element technique with relatively good sensitivity and 
selectivity when configured correctly. This technique utilizes the plasma as an ion 
source or light emission source are capable of producing values. 
 
QUANTITATIVE ESTIMATION OF HEAVY METALS BY ICP-OES: 
Instrumentation parameters:  
Instrument name: Inductive coupled plasma-Optical emission spectroscopy 
Instrument Model: PE Optima 5300DV ICP-OES; Optical system Dual view-axial 
or radial 
Detector system: Charge coupled detector, (UV-Visible detector which is 
maintaining at -40º C) to detect the intensity of the emission line. 
Light source (Torch): Positioned horizontally in the sample compartment along the 
central axis of the spectrometer optics. Changing from axial to radial viewing is a 
simple software command and is accomplished by computer control of a mirror 
located in the optical path. The torch assembly of this system comprises of two 
concentric quartz tubes. 
Standard alumina injector: 2.0mm inner diameter.  
Spray chamber: Scott type 
Nebulizer: Cross flow gem tip. 
Preparation of sample by acid digestion method: 
50mg of powder was treated with acid mixture of sulphuric acid: water in the 
ratio of 4:1in the Kjeldahl flask and heated continuously till the solution is colourless. 
The sample mixture was then transferred in a 25ml volumetric flask and made up to 
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the volume with distilled water. Blank solution was prepared as above without 
sample. 
The standards of Arsenic, Lead, Mercury and Cadmium were prepared as per 
the protocol and the calibration curve was developed for each of them. 
Detection: 
            Samples were analyzed for the detection and quantification of the calcium, 
sulphate, borate, silver, aluminium, copper, potassium, chloride by Inductively 
Coupled Plasma Emission Spectrometry. 
  
PHYTOCHEMICAL STUDIES 
PRILIMNARY PHYTOCHEMICAL SCREENING 
89-91 
Phytochemical evaluation is used to determine the nature of phyto constituents 
present in the plant by using suitable chemical tests. It is essential to study the 
pharmacological activities of the plant. It can be done by confirmation with different 
chromatographic techniques like TLC and HPTLC. Therefore a complete 
investigation is required to characterize the Phyto constituents qualitatively and 
quantitatively. 
Extraction 
The first step was the preparation of successive solvent extracts. The dried 
coarsely powdered sample of Erythrina variegata was first extracted with Petroleum 
ether  (60-80°C) in Soxhlet apparatus and then with solvents of  increasing polarity 
like Chloroform, Ethyl acetate and Ethanol at 60 - 70ºC. They were then followed 
with maceration in aqueous solvent. Each extract was concentrated using rotary 
vacuum evaporator. The percentage yield, colour and consistency of these extracts 
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were recorded and preceded for further detailed phyto chemical and pharmacological 
screening. 
 
PRELIMINARY PHYTOCHEMICAL SCREENING 
 
The chemical tests for various Phyto constituents in the dried powder and 
extracts of leaves of Erythrina variegata Linn., were carried out as described below 
and the results were recorded. 
Detection of Flavonoids  
 Shinoda test : 
           To the solution of extract,  few piece of magnesium turnings and 
concentrated Hcl was added drop wise, pink to crimson red, occasionally 
green to blue color appears after few minutes indicates the presence of 
flavonoids. 
 Alkaline reagent test : 
           To the test solution  few drops of sodium hydroxide solution was 
added, intense yellow color is formed which turns to colorless on addition of 
few drops of dilute acid indicate presence of flavonoids.  
 
Detection of Alkaloids  
 Dragendorff’s reagent : 
             The substance was dissolved in 5ml of distilled water, to this 5ml of 
2M HCL was added until an acid reactions occurs, then 1ml of Dragendorff’s 
reagent was added and examined for an immediate formation of an orange red 
precipitate. 
 Mayer’s reagent: 
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           The substance was mixed with little amount of dilute hydrochloric acid 
and Mayer’s reagent and examined for the formation of white precipitate. 
 Wagner’s reagent : 
            The test solution was mixed with Wagner’s reagent and examined for 
the formation of reddish brown precipitate. 
Detection of Carbohydrates 
 Molisch’s test : 
              To the test solution few drops of alcoholic alpha napthol and few 
drops of conc. sulphuric acid were added through the sides of test tube, purple 
to violet color ring appears at junction. 
 Fehling’s test : 
              The test solution was mixed with Fehling’s I and II and heated and 
examined for the appearance of red coloration for the presence of sugar. 
Detection of Gum and Mucilage 
               Small quantities of test substances was dissolved in 5 to 10ml of 
acetic anhydride by means of heat, cooled and add 0.05ml of concentrated 
sulphuric acid; it is examined for the formation of bright purplish red color. 
Detection of Proteins  
 Biuret test : 
The sample was treated with 5-8 drops of 10% w/w copper sulphate 
solution, violet color   is formed.  
Detection of fats and fixed oils: 
                Small quantities of extracts were pressed between two filter papers. 
An oily stain on filter paper indicates the presence of fixed oils and fats. 
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Detection of Steroids: 
 Libermann Burchards Test: 
            The powdered drug was treated with few drops of acetic anhydride, 
boiled and cooled. Conc.sulphuric acid was added from the sides of the test 
tube, brown ring is formed at the junction of two layers and upper layer turns 
green which shows presence of steroids and formation of deep red color 
indicates presence of tri terpenoids.. 
Detection of Glycosides  
 Borntrager’s test : 
             The powdered material was boiled with 1ml of sulphuric acid in a test 
tube for five minutes. Filtered while hot, cooled and shaken with equal volume 
of chloroform. The lower layer of solvent was separated and shaken with half 
of its volume of dilute ammonia. A rose pink to red colour is produced in the 
ammonical layer. 
 Modified Borntrager’s test : 
            The test material was boiled with 2ml of the dilute sulphuric acid. This 
was treated with 2ml of 5% aqueous ferric chloride solution (freshly prepared) 
for 5 minutes, and shaken with equal volume of chloroform. The lower layer 
of solvent was separated and shaken with half of its volume of dilute 
ammonia. A rose pink to red colour is produced in the ammonical layer.  
. Detection of Phenols  
 Ferric chloride test : 
               A small quantity of substance were dissolved with 2ml distilled 
water and a few drops of 10% aqueous ferric chloride solution was added and 
observed for appearance of blue or green color.  
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Detection of Saponins  
               A drop of sodium bicarbonate solution was added to the sample and 
the mixture was shaken vigorously and left for 3 minutes. Development of any 
honey comb like froth was examined. 
 
QUANTITATIVE ESTIMATION OF TOTAL PHENOLIC AND TOTAL 
FLAVONOID CONTENT
93-95 
 
TOTAL ALKALOID CONTENT 
                 Accurately measured aliquots (0.4, 0.6, 0.8, 1 and 1.2ml) of atropine 
standard solution were transferred to different separating funnels. Then 5ml of Ph 4.7 
phosphate buffer and 5ml of BCG solution were added the mixture was shaken with 
1, 2, 3 and 4ml of chloroform. The extracts were collected in a 10 ml volumetric flask 
and then diluted to adjust the volume with chloroform was measured at 470nm against 
blank prepared as above but without atropine.  
 
TOTAL FLAVONOID CONTENT 
Total flavanoid content was determined by calorimetric method, using 
quercetin as a standard. The test samples were individually dissolved in DMSO. Then 
the sample solution (150 µl) was mixed with 150 µl of 2% aluminium chloride. After 
10min of incubation at ambient temperature, the absorbance of the supernatant was 
measured at 435nm using spectrophotometer. Three replicates were made for each test 
sample. The total flavanoid content was expressed as quercetin equivalent in mg/gm 
extract (mg QRT/gm extract). 
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TOTAL PHENOLICS CONTENT (Folin – Ciocalteu’s assay) 
Total phenolic content of the extracts were determined using Folin –
Ciocalteu’s assay. 0.5ml extract solutions were mixed with 2.5ml of 10 fold diluted 
Folin Ciocalteu’s reagent and 2.5ml of 7.5% sodium carbonate. After incubation at 
40°c for 30 minutes, the absorbance of the reaction mixtures was measured at 765nm 
in a spectrophotometer. Three replicates were made for each test sample. Gallic acid 
was used as a standard and total phenolic content of the extract was expressed in mg 
of Gallic acid equivalents (mg GAE/g extract).  
 
FLUORESCENCE ANALYSIS
92
 
 
Fluorescence analysis was carried out in day light and in UV light. The leaf 
powder and extracts were treated with different solvents and the fluorescence was 
observed in day light and in near and far UV light.    
 
CHROMATOGRAPHY
 96-98 
Chromatography methods are important analytical tool in the separation,                          
identification and estimation of components present in the plant. 
THIN LAYER CHROMATOGRAPHY 
Principle 
Thin layer chromatography is a technique used for the separation, 
identification and estimation of single or mixture of components present in the various 
extracts. It is reliable technique in which solute undergoes distribution between two 
phases, stationary and mobile phase. The separation is mainly based on the 
differential migration that occurs when a solvent flows along the thin layer of 
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stationary phase. This may be achieved by partition and adsorption depending on 
stationary phase used. 
TLC Plate Preparation 
The plates were prepared using Stahl TLC spreader. 40gm of silica gel G was 
mixed with 85ml of water to prepare homogenous suspension and poured in the 
spreader. 0.25mm thickness of plates was prepared, air dried until the transparency of 
the layer disappeared, then dried at 110°C for 30 minutes and kept in desiccators. 
Selection of mobile phase:   
Solvent mixture was selected on the basis of the phyto constituents present in 
each extract. Factors such as nature of components, stationary phase, mobile phase, 
polarity, influence the rate of separation of constituents. From the vast analysis, best 
solvent was selected which showed good separation with maximum number of 
components.  
 
               
                  Distance travelled by solute from the origin 
Rf  = 
                 Distance travelled by solvent from the origin 
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HIGH PERORMANCE THIN LAYER CHROMATOGRPHY 
99 
The alcoholic extracts of leaf of the plant were subjected to HPTLC method 
for identification for the phytoconstituents. 
Solvent system  
The solvent system optimized for HPTLC was  
Chloroform : Methanol : Formic acid : Water (65:25:10:5) 
Application of sample  
A small quantity of extract was dissolved in Methanol and sample was applied in 
precoated plate with the help of Linomet V applicator.  
Development of Chromatogram  
A rectangle twin trough glass chamber was used in the experiment. To avoid 
insufficient chamber saturation and the undesirable edge effect, a smooth filter paper 
was placed in the glass chamber and was allowed to be soaked in the developing 
solvent. The moistened paper was pressed against the walls of the chamber so that it 
adheres to the walls. The chamber was allowed to saturate for 15min before use. The 
experiment was carried out at room temperature in diffused day light.  
Procedure  
The plate was dipped in a saturated chromatographic chamber containing the 
solvent system and was allowed to elute up to 8 cm and was air dried. The spots were 
scanned in CAMAG TLS scanner-3.  
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HPTLC of alcoholic extract of Erythrina variegata leaf  
Sample : Alcoholic extract  
Stationary phase : HPTLC precoated, with silica gel G 60 F254 as 
adsobent (Merck, Germany) 
Mobile Phase : Chloroform : Methanol : Formic acid : Water 
(65:25:10:5) 
Sample Concentration : 10 mg/ml 
Applied volume : 5.0 and 10.0 µl 
Size of the plate : 10 × 10 cm 
Developing chamber : Twin trough glass chamber 
Mode of application : Band  
Band size : 5 mm 
Separation technique : Ascending  
Temperature :    60
0
 C 
Saturation time : 5 min 
Scanning wavelength : 254 nm/ 366nm 
Scanning mode : Absorbance / Reflectance    
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SELECTION OF ACTIVE EXTRACT 
IN VITRO ANTI OXIDANT ACTIVITY 
103 
DPPH Assay:  1, 2-DIPHENYL-2-PICRYL HYDRAZYL RADICAL (DPPH)
 
Initial volume 0.1 mL of various concentrations of samples was mixed with 
0.4 mL of 0.3M DPPH reagent prepared in ethanol. The mixture was shaken 
thoroughly and incubated in the darkness at room temperature for 30 min. The 
absorbance of the reaction was measured spectrophotometrically at 517nm, 
immediately after mixing and then after incubation as well. The scavenging effect of 
DPPH free radical was calculated by using the following equation. 
 
% scavenging activity = Abs (control) - Abs (standard) / Abs (control) × 100  
 
Where control is the absorbance of the blank (a reaction with all the reagents 
except the test extract), and absorbance of sample is the absorbance of the test extract. 
Tests were carried out in triplicates to obtain 50% inhibition (IC50). Using Butylated 
hydroxy Toulene. 
 
HYDROGEN PEROXIDE SCAVENGING ASSAY (HPSA) 
104-105 
                   
The ability of the extracts to scavenge hydrogen peroxide was determined 
according to the method of  Ruch. A solution of Hydrogen peroxide (2mmol/l\lt) was 
prepared in phosphate buffer (PH 7.4). Various concentrations of extracts (10-
100µg/ml) were added to hydrogen peroxide solution (0.6ml).  Absorbance at 230nm 
was determined after 10min against a blank solution containing phosphate buffer 
without hydrogen peroxide. 
% Scavenging activity = Abs (control) - Abs (standard) / Abs (control) × 100 
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PHARMACOLOGICAL STUDIES: 
ACUTE ORAL TOXICITY STUDY (OECD 423 GUIDELINES)
 47  
Literature survey showed that acute toxicity of the extracts was determined 
according to the OECD guideline No. 423. Male albino mice weighing 27-30 g were 
used for ethanolic Extract of Erythrina variegata Linn.,  was given to four groups  
(n = 5) of animals each at 5, 50, 300 and 2000 mg kg-1 b.w. p. o. The treated animals 
were under observation for 14 days, for mortality and general behaviour. No death 
was observed till the end of the study. The test sample was found to be safe up to the 
dose of 2000 mg/kg.  So, 1/10
th
 and 1/5
th
 of the dose (200 and 400mg/kg) were 
selected for this study.  
IN VIVO EVALUATION OF LETROZOLE INDUCED POLYCYSTIC 
OVARIAN DISEASE   
The protocol for conducting the In Vivo study in female adult albino wistar rat 
was approved by the Institutional Ethical Committeee (ICE) of the Madras Medical 
College, Chennai – 600003 India. 
 Approval no : IAEC/MMC/06/2016. Dated : 21.11.2016 
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EXPERIMENTAL DESIGN 
27, 106,107  
Materials and Methods 
Plant extract 
Ethanolic extract of leaves of Erythrina variegata Linn.,   
Animal selection and procurement 
Healthy young female wistar albino rats (weighing about 150 – 200 gm) were 
procured from the Madras Medical College animal house. 
The procured animals were kept in a clean, dry polycarbonate cages and 
maintained in a well-ventilated animal house. The temperature of experimental animal 
room was maintained at 22ºC (± 3ºC) and the relative humidity was maintained from 
50-60%. Lighting was artificially maintained for 12hrs dark and 12hrs light. All the 
animals were kept in the cages for at least 5days prior to dosing for acclimatization to 
the laboratory conditions. The animals were fed with standard pellet diet and water 
was given ad libitum. Before starting the dose, the animals were fasted overnight but 
allowed to access water. 
 
PCOS induction  
All the experimental animals except Control group, were orally administered 
with LETROZOLE at a dose of 1mg / kg dissolved in 0.5% Carboxy Methyl 
Cellulose (CMC) once daily for 21 days. Control group received vehicle only (0.5 % 
CMC). Vaginal Smears were collected daily and evaluated microscopically using 
Crystal violet stain to confirm the induction of PCOS. 
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STUDY DESIGN  
The study consisted of 30 female  wistar albino rats equally divided into five 
groups designated as Group I (served as control group), Group II (served as PCOD 
induced group), Group III (served as standard group), Group IV and V served as 
treatment groups. Following LETROZOLE administration, standard group was 
administered with Metformin at a dose of 1 mg/kg in per oral route and treatmennt 
groups IV and V were administered Ethanolic extract of Erythriva variegata  Linn.,  
with the dose of 200mg/kg  (Group IV) and 400 mg/kg (Group V)  body weight 
respectively in 0.5% CMC per oral for 22 to day 52.  
 
The animals received following treatment  
A total of 30 Adult female wistar albino rats are divided into 5 groups of 6 
animals each 
Table 6. GROUPING OF ANIMALS   
S.NO GROUP INDUCTION TREATMENT  
for 30 days 
NO OF 
ANIMALS 
1 I  Control Normal saline orally Normal saline orally 6 
2 II  Disease 
control 
1 mg/kg Letrozole 
OD for 21 days 
Normal saline orally 6 
3 III Standard 1 mg/kg Letrozole 
OD for 21 days 
Metformin 100 mg/kg 
orally 
6 
4 IV Test 
group 
(200 mg/kg) 
1 mg/kg Letrozole 
OD for 21 days 
200 mg/kg ethanolic 
extract orally 
6 
5 V Test group 
(400 mg/kg) 
1 mg/kg Letrozole 
OD for 21 days 
400 mg/kg ethanolic 
extract orally 
6 
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EVALUATION PARAMETERS  
 Body weight     
 Food intake 
 Vaginal exfoliative cytology  
 Determination of blood glucose level  
 Lipid profile  
 Weight of Reproductive organ (Uterus and Ovary) 
 Histopathological evaluation (Uterus and Ovary) 
Body weight  
Initial body weight of animals in all groups were determined on the first day. 
The body weight of different groups of rat were noted weekly for 2 months. 
Food intake  
100 g of weighed rat feed was given to six groups and the residue  of food 
intake was weighed. 
Vaginal exfoliative cytology   
Smear technique – Lavage or Washing with saline or Water from pipette  
A small amount (approximately 0.2ml) of saline or distilled water is drawn up 
into the pipette tip. The rat is held around the thorax, ventral surface uppermost, with 
one hand whilst the hand holding the pipette is used to restrain the tail, to provide 
additional support and help prevent the animal struggling.  
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The tip of the pipette is pushed gently into the entrance of the vagina to a 
depth of 2-5 mm and the fluid is flushed into the vagina and back up into the pipette 
two or three times by gently squeezing and releasing the bulb of the pipette. A small 
amount of the cell suspension is then expelled onto a labelled glass slide. Slides 
should be labelled with the female identification numbers; the data and study number 
may also be shown but as the smears are discarded immediately  after reading this is 
not usually considered necessary as long as the tray holding the slides is identified 
appropriately. 
Crystal violet stain was added to the slide to cover the smear. The slide was 
kept covered in petridish for 5 min. Distilled water was added to the crystal violet 
stain and gently rocked. A violet scum appeared on top of the slide. The slide was 
stained for 10 min in dilute crystal violet stain. The stained slide was dried and then 
washed in tap water. The washed slide was air dried and observed under the 
microscope in 40× objective.   
Stages of estrus cycle in rat  
During the study, vaginal smears were observed microscopically using Crystal 
violet stain for determination of estrus cyclicity.   
4 stages of estrus cycle is seen in female rat  
Proestrus  
      It is a preparatory phase to the next estrus phase. Vaginal smear shows 
nucleated epithelial cells. This stage is last for about 12 hrs.  
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Estrus  
The vaginal smear shows 100% cornified epithelial cells. This stage is last for 
9-15 hrs.  
Metestrus  
It follow after estrus stage, the vaginal smear shows many leucocytes with a 
few cornified cells. This stage is last for 20 hrs.  
Diestrus  
It is the longest phase, consists of mainly leucocytes in vaginal smear. This 
stage is last for 57 hrs.  
Preparation of Blood Serum 
After 21 days, PCOS control group and after 52 days, animals from other 
groups were fasted overnight and anaesthetized with diethyl ether. Blood was 
collected by retino orbital puncture then serum was separated by centrifugation and 
was used for estimation of blood glucose, lipid Profile .  
Determination of Blood Glucose Level  
The blood glucose level of each group were monitored at the end of the study.  
Lipid Profile  
Lipid profile which includes total cholesterol (TC), triglycerides TGs), low-
density lipoprotein (LDL) and high density lipoprotein (HDL)  were estimated by 
autoanalyzer microlab 200 using Ecoline-kits. 
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Weight of Reproductive organ  
Uterus and ovaries were dissected out from each animal and weighed by a 
digital electronic weighing balance to evaluate the effect of the extract.  
Histopathological evaluation  
The isolated samples of ovaries and uterus in each group were selected for 
histopathological evaluation. The tissues placed in 10% buffered formalin. The fixed 
tissues were stained with Haematoxylin and Eosin. Slides were reviewed for the 
evaluation of histopathological changes like follicles, carpus luteum and cysts.  
Statistical analysis  
Results were expressed as Mean ± SEM. The data was analyzed using one 
way analysis of variance (ANOVA) followed by Dunnett’s test. P values < 0.01 were 
considered as Significant.  
COLUMN CHROMATOGRAPHY FOR ISOLATION AND 
IDENTIFICATION OF PHYTOCONSTITUENTS
 
Ethanol extract was selected for the isolation and identification of 
phytoconstituents.  
 A suitable column of 2.5 cm in diameter and 60 cm in length was selected and 
thoroughly washed with water, dried and rinsed with acetone and then dried 
completely. Little pure cotton was placed into the bottom of the column with the help 
of a big glass rod up to neck to avoid the leakage of smaller particles of the adsorbent. 
 
 Ethanol extract (3 gm) was mixed with silica gel (200 to 400 mesh size) in the 
ratio of 1: 2 to form a free flow of the extract. It was loaded in the column by wet 
packing method using n-Hexane. Silica gel (200 to 400 mesh size) was made in to 
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slurry with n-Hexane and it was packed in the column. Pure cotton was placed over 
the silica gel. The extract was packed in the column through the funnel. Again pure 
cotton was placed over the extract. 
 
 The column was developed by elution with n-Hexane and then followed by n-
Hexane : Chloroform (75:25, 50:50, 25:75), 100 % Chloroform, Chloroform : Ethyl 
acetate (75:25, 50:50, 25:75), 100 % Ethyl acetate, Ethyl acetate : Ethanol  (75:25, 
50:50, 25:75) in gradient manner and finally exhausted using 100 %  Ethanol. The 
liquid level was always kept above the surface of the column to prevent the cracking 
of the column. Fractions of 50 ml were collected and monitored by TLC on silica gel 
with various mobile phases and visualized in iodine chamber as well as in UV light. 
TLC 
 
As soon as the fraction eluted, it was analyzed by using ready made TLC plate 
with suitable mobile solvent according to the polarity of elute.  
SOLVENT  
Chloroform : methanol (9:1).  
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Observation 
The developed chromatogram was observed under UV, Fluorescence and also 
derivatised using detecting agent. 
Ethanolic extract of 
Erythrina variegata Linn., 3g 
 
 
 
Column chromatography silica gel. 
Hexane, ethyl acetate, ethanol gradient elution. 
 
 
                                                         
Fraction I                   Fraction II 
 
                                    
Very little and had          Narrow band, 
very several spots          single spots. 
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CHARACTERISATION OF ISOLATED COMPOUNDS 
PHYSICAL EVALUATION: 
1. Physical properties of the isolated compounds are evaluated, such as 
 Colour 
 Nature 
 Solubility 
 Molecular weight 
 Molecular formula 
2. Further the isolated compounds were characterized by following 
Spectroscopic methods. Such as 
               IR Spectroscopy 
               Gas Mass spectroscopy 
 
IR SPECTROSCOPY 
100 
Infrared (IR) spectroscopy is one of the most common spectroscopic 
techniques used by organic chemists. The main goal of IR spectroscopic analysis is to 
determine the chemical functional groups in the sample. Different functional groups 
absorb characteristic frequencies of IR radiation. IR spectroscopy is an important and 
popular tool for structural elucidation and compound identification. The possible 
characteristic bands of the nucleus are 
                     1. 3540-3300 cm-1 N-H Stretching Vibration 
                     2. 3670-3230 cm-1 O-H Stretching Vibration 
                     3. 1690-1630 cm-1 C=N Stretching Vibration 
                     4. 2975-2840 cm-1 C-H Aliphatic Stretching Vibration 
                     5. 3100-3000 cm-1 C-H Aromatic Stretching Vibration 
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GAS – MASS CHROMATOGRAPHY 
101 - 102
  
It is a combined technique, used for molecular weight determination. Gas 
chromatography and mass spectroscopy combined to form GC-MS.  
GC-MS information 
Make  : Perkin Elmer 
GC model : Clarus 680 
Mass Spectrometer : Clarus 600 (EI) 
Software : TurboMass ver 5.4.2 
Library  ver :  NIST-2008 
ACQUISITION PARAMETERS 
Oven : Initial temp 60°C for 2 min, ramp 10°C/min to 300°C, hold 
6 min, 
Total Run Time :  32.00 mint 
Inj auto : 260°C,  
Volume                 : 1 μL,  
 Split                     : 10:1, 
Flow Rate             : 1 mL/mint 
Carrier Gas           : He, 
Column                : Elite-5MS (30.0m, 0.25mmID, 250μm df) 
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MASS CONDITION (EI) 
Solvent Delay      : 2.00 min, 
Transfer Temp     : 240°C, 
Source Temp        : 240°C, 
Scan                      : 50 to 600Da, 
 
GC-MS analysis 
 The Clarus 680 GC was used in the analysis employed a fused silica column, 
packed with Elite-5MS (5% biphenyl 95% dimethylpolysiloxane, 30 m × 0.25 mm ID 
× 250μm df) and the components were separated using Helium as carrier gas at a 
constant flow of 1 ml/min. The injector temperature was set at 260°C during the 
chromatographic run.  The 1μL of extract sample injected into the instrument the oven 
temperature was as follows: 60 °C (2 min); followed by 300 °C at the rate of 10 °C 
min−1; and 300 °C, where it was held for 6 min.  The mass detector conditions were: 
transfer line temperature 240 °C; ion source temperature 240 °C; and ionization mode 
electron impact at 70 eV, a scan time 0.2 sec and scan interval of 0.1 sec. The 
fragments from 40 to 600 Da. The spectrums of the components were compared with 
the database of spectrum of known components stored in the GC-MS NIST (2008) 
library. 
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SURVEY OF POLYCYSTIC OVARIAN DISEASE  
16,17
  
OBJECTIVE OF THE STUDY 
 
 Identify the adolescent girls who are at high risk for PCOS. 
 Find association between PCOS risk status with selected variable general 
health status. 
 The major purpose of this study is to create awareness among adolescent 
college girls. This will help them to modify their life style and to have better 
reproductive life later.  
CRITERIA USED FOR DIAGNOSING PCOS 
20, 21 
 
NH / NICHHD 1990 or NHI STATEMENT  
       
 To include all of the following 
1) Hypernandrogenism and / or Hyperandrogenemia 
2) Oligo-ovulation 
3) Exclusion of hypothyroidism, Hypoprolactinemia, Cushing’s syndrome, 
NCAH, Androgeen secreting tumors and exogenous androgen intake. 
 
ROTTERDAM 2003 or ESHRE / ASRM statement 
        
  To include all of the following in addition to exclusion of related disorder 
1) Clinical and / or biochemical hyperandrogenism 
2) Oligo-ovulation or anovulation 
3) Polycystic ovaries ( exclusion of other endocrinopathies) 
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AE – PCOS 2006  
         
 To include all of the following 
1) Clinical and / or biochemical hyper androgenism with either. 
2) Oligo-anovulation  
3) Polycystic ovaries ( exclusion of other androgen excess of related 
disorders.  
MATERIALS AND METHODS  
 
The medical history was recorded, with Anthropometric, clinical and 
biochemical parameters by using the questionnaire on whether the participant had 
been previously diagnosed with PCOS. Menstrual irregularity was assessed as a usual 
cycle of less than 21 days or more than 35 days. Clinical hyprandrogenism was 
assessed on the basis of the self-reported degree of hirsutism by using self assessment 
method. Results were kept confidential. The selected participants likely to have PCOS 
asked to go or further clinical and ovarian ultra sound examination.  
 
This is a questionnaire based study on the awareness of polycystic ovary 
syndrome. The participants who undertook the students of a college and working 
womens.  A total of 29 questions were asked to 232 girls of age group between 17-34 
yrs. Individuality was assured when the subjects filled the survey. The questionnaire 
is filled in paper and pen method. After the data collection, statistical measurements 
were applied. The questions included  are ; 
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The questionnaire  
Anthropometric, clinical and biochemical parameters  
(1)   Age _________yrs. 
(2)   Height _________ cms. 
(3)   Weight _________kg. 
(4)   Body Mass Index (BMI) _____________kg/m
2 
 (calculated). 
(5)   Waist circumference__________ (cm).  
(6)   Hip circumference  __________ (cm). 
(7)   Age at menarche  _____________. 
(8)   Regularity of the menstrual cycle __________(yes or no). 
(9)  Pelvic pain during menstruation  _____________(yes or no). 
(10)  Marital status   __________________  If  Married (yes or no). I yes answer 12 
& 13. 
(11)  Fertility problems  ____________(yes or no). 
(12)  Use of oral contraceptive Pills  __________(yes or no). 
(13)  Presence of PCOD________________ If Yes, Answer the following 
(14)  Diet ______________(what type of diet is taken). 
(15)  Craving for carbohydrates and sugar _______________(yes or no).  
(16)  Obesity___________(yes or no). 
(17)  Blood pressure________ (mmHg) 
(18)  Symptoms of hypoglycemia ________________(yes or no) . 
(19)  Serum FSH and LH level___________ and __________(ng/dl) 
(20)  Serum Testosterone level__________(ng/dl) 
(21)  Hirsutism (Unwanted hair growth) of face and body____________ 
(22)  Acne___________________(yes or no). 
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(23)  Stretch marks (Stria) _____________ 
(24)  Hair loss_____________(yes or no). 
(25)  Acanthosis nigricans (Skin disorder) __________(yes or no). 
(26)  Other systemic disorders ( or ×) 
Diabetes_________ ,   Hyperthyroidism____________ ,  
Hypertension ____________,  High Cholesterol _______,  
Depression and mood change_________, Stress ________. 
(27)  Family History : Your Mother with PCOD__________, Your siblings with 
PCOD__________.  
(28) Have you everbeen come across the term PCOD? __________. 
(29)  If yes, how did you know about  PCOD? __________.  
Fig 8.Questionnarie filling, 
 
 
 
 
 
 
 
 
 
 
 
 
  Fig 9. Height  determination        Fig 10. Weight Checking 
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RESULTS AND DISCUSSION 
PHARMACOGNOSTICAL STUDIES 
Organoleptic characters :  
Nature – Coarse powder 
Taste – No characteristic   
Odour      – Unpleasant   
Colour     – Dark green   
MACROSCOPY  
Type                 – Trifoliate, Alternate, Compound 
Shape               – Rhomboid, Heart shaped 
Margin             – Entire 
Apex                 – Acuminate 
Base                  – Obtuse   
Size                   – 14-16 cm in length 
                              13-15 cm in breadth 
Surface             – Upper – Smooth dark green  
Lower  – Smooth pale green    
Texture             – Fine  
Venation           – Reticulate   
Leaflets            – Triangular medium   
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MICROSCOPIC  FEATURES  
Transverse section of leaf:  
In transectional view, the leaf exhibits thick midrib and uniformly thick and 
smooth lamina (fig 11). The midrib consists of wide, conical, short thump and wide 
semicircular abaxial part of the midrib. The midrib is 1.1mm thick and the abaxial 
semicircular part in 1mm wide.  
T.S of Midrib - enlarged   
The vascular system of the midrib includes adaxial, median collateral vascular 
bundles, two lateral vascular bundles and a wide are of three discrete abaxial median 
bundles (fig 12).  
T.S of Midrib – Upper portion 
The adaxial median vascular bundles has a cluster of large angular, thick 
walled vessels and three vertically elongated phloem units to eated other adaxial side, 
there is a thick and wide sclerenchyma cells placed above the adaxial medium bundle 
(fig 13).  
T.S of Midrib – Lower  portion 
The epidermis of the midrib consists of small squarish the cell walled cells 
2mm squarish epidermis occur six in seven layers of fairly wide, angular, thick walled 
and compact parenchyma cells (fig 14). There is a wide bowl shaped layer of 
schlerenchyma cell enclosing. The schlerenchyma layer is two to four cells thick.  
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The lateral and abaxial are of vascular bundles are all collateral with wide 
mass of randomly placed thick walled angular vessels and many independent units of 
small mass of phloem elements. 
Calcium Oxalate Crystals (Druses) in the Adaxial part of the Midrib 
Calcium oxalate crystals fairly widely distributed in the midrib and leaf (fig 
15). In the midrib the crystals are drusen located in the parenchyma cells inside the 
adaxial epidermal layer.  
Prismatic crystals in Lamina  
The leaf crystals are mostly prismatic type and are seen along the veins of the 
lamina (fig 16).  
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MICROSCOPIC FEATURES OF THE LEAVES 
TRANSVERSE SECTION OF THE LEAVES 
Fig 11. T.S of leaf through midrib 
        
La-Lamina, AdVB-Adaxial vascular bundle, AdH-Adaxial Hump,  
MR-Midrib,  AbVB-Abaxial vascular bundle, Scl-Sclerenchyma. 
Fig 12 : T.S of Midrib – enlarged 
     
AdE-Adaxial Epidermis, PM-Palisade Mesophyll, Ph-Phloem, X-Xylem, LB-Lateral 
bundle, GPa-Ground Parenchyma. 
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Fig 13. T.S of Midrib – Upper portion 
                       
AdVB-Adaxial vascular bundle, Scl-Sclerenchyma, Ph-Phloem, MX-Meta Xylum 
Fig 14.  T.S of Midrib – Lower portion 
 
AbVB-Abaxial vascular bundle, Scl-Sclerenchyma, Ph-Phloem, MX-Meta Xylum 
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Fig 15. Calcium Oxalate Crystals (Druses) in the Adaxial part of the Midrib 
            
AdH – Adaxial Hump, Cr – Crystals , Ep – Epidermis, Scl - Sclerenchyma 
Fig 16. Prismatic crystals in Lamina 
        
  
Ep – Epidermis, Cr – Crystals 
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POWDER MICROSCOPY  
It  was also observed that wide drusan occur in large clusters in the mesophyll 
tissue of the  lamina ( Fig 17). Apart  from  druses and prismatic crystals, these also 
another type of crystals called double – cystolith (Fig 18). These crystals are 
elongated, cylindrical and occur in pairs, end to end.   
Fig. 17:  Druses in leaf mesophyll                   Fig. 18: Double Cystolith in lamina 
   
               Dr – Druses                                                    DCy – Double Cystolith 
EPIDERMAL TISSUE :                                  
 Adaxial epidermal cells in surface view 
Epidermal cells and stomatal morphology were studied in surface view of the 
epidermal peeling. The adaxial epidermis is nonstomatic the epidermal cells have 
slightly wavy undulate anticlinal walls which are thin and smooth. The costal cells 
forming the veins of the lamina, are vertically elongated with straight walls (Fig.19).  
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Fig 19. Adaxial epidermal cells in surface view 
    
AdE-Adaxial Epidermis,  AW - Anticlinal Wall, EpC- Epidermal Cells, CC- Coastal 
Cells 
Abaxial epidermis 
The abaxial epidermis is densely stomatierous. The epidermal cells have thick 
undulate anticlinical walls. The cells possess prominent nuclei and other cell 
inclusions (Fig 20). The stomata are broadly elliptical and have  thick walls. The 
stomatal  pore in narrow and slit like the guard cells are 20-25µm long and 20µm 
thick.  
Paracytic Stomata – enlarged  
The stoma has two subsidiary, one on either side of the guard cells and parallel 
of the long axis of the stoma. The stomata are paracytic type. (Fig 20, 21)   
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Fig 20. Abaxial epidermis showing stomata 
 
 
 
 
 
 
EC - Epidermal cells, AW–Anticlinal  Walls, St - Stomata, 
Fig 21. Paracytic stomata enlarged 
 
Sc - Subsidiary cells, Nu-Nucleus 
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Glandular trichome  
Thick, short, elliptical much cellular glandular trichomes (Fig. 22)  are 
common on the lamina. The gland has a short wide stalk cells of the gland stand erect. 
The gland has about row of four cells, the cells being arranged one above the other.  
 
Fig. 22 Glandular trichome 
 
GTr – Glandular Trichome, BC – Basal cells 
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LEAF CONSTANTS  
Table 7 : Leaf constants of Erythrina variegata Linn., 
 
S.NO 
 
PARAMETERS  
 
 
Values in sq mm 
 
1 
 
Stomatal no (upper epidermis)  
 
 
6 – 8 
 
2 
 
  
Stomatal index (upper epidermis) 
 
18.18 – 22.32 
 
3 
 
 
Stomatal no (lower epidermis) 
 
10 – 12 
 
4 
 
 
Stomatal index (lower epidermis) 
 
15.05 – 20.01 
 
5 
 
 
Vein islet number 
 
24 – 28 
 
6  
 
Veinlet termination number 
 
12 – 14 
 
LINEAR MEASUREMENT OF CALCIUM OXALATE CRYSTALS 
Table 8 : Quantitative microscopy – linear measurement of  
calcium oxalate crystals 
 
PARAMETERS 
 
MINIMUM 
(µm) 
 
AVERAGE (µm) 
 
MAXIMUM (µm) 
 
 
 Length 
 
 
125 
 
298 
 
572 
 
 
Width  
 
12.8 
 
16.4 
 
26.8 
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HISTOCHEMICAL STUDIES   
Table 9 : Histochemical Color Reaction Erythrina variegata Linn., 
S.no Chemicals Test for Nature of 
change 
Histology Degree 
of 
change 
 
1 
 
Phloroglucinol + 
HCl 
 
Lignin 
 
Pink 
 
Xylem 
 
+  
 
 
2 
 
N / 50 Iodine 
Solution 
 
Starch 
 
Blue 
 
Middle layer 
near oil 
globules 
 
+ 
 
 
3 
 
Dil. Ferric Chloride 
 
Tannin 
 
Black 
 
Vascular 
bundles 
 
+ 
 
 
4 
 
Picric acid 
 
Protein 
 
No yellow 
color 
 
-- 
 
- 
 
5 
 
 
Dragendroff’s 
reagent 
 
Alkaloid 
  
Orange 
color 
 
Middle layer  
 
+ 
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 PHYSIOCHEMICAL CONSTANTS  
Table 10 : Physiochemical Constants  of Erythrina variegata Linn., leaves 
S.NO PARAMETERS VALUES (%W/W) 
I ASH VALUE 
1. Total ash 9.48±0.67 
2. Water insoluble ash 6.9±0.26 
3. Acid soluble ash 0.73±0.75 
4. Sulphated ash 4.2±0.42 
II EXTRACTIVE VALUE 
1. Water soluble extractive 4.37±0.82 
2. Alcohol soluble extractive 6.65±0.45 
3. Ether soluble extractive  7.25±0.58 
4. Non volatile ether soluble extractive 12.17±0.17 
IV LOSS ON DRYING  5.11±0.52 
V FOAMING INDEX  Nil 
VI SWELLING INDEX  Nil 
VII VOLATILE OIL CONTENT Nil  
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INORGANIC ELEMENTS AND HEAVY METALS   
Table 11 :  Qualitative Estimation of Inorganic Elements of  
Erythrina  variegata Linn., 
S.No INORGANIC ELEMENTS OBSERVATIONS 
1.  Aluminium 
 
+ 
2.  Chloride 
 
+ 
3.  Calcium 
 
+ 
4.  Iron 
 
+ 
5.  Borate 
 
+ 
6.  Potassium 
 
+ 
7.  Carbonate 
 
- 
8.  Sulphates 
 
- 
9.  
 
Silver + 
10. Nitrate + 
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Table 12 :  Quantitative  Estimation Of Inorganic Elements of  
Erythrina variegata Linn., 
S.NO INORGANIC 
ELEMENTS 
TOTAL AMOUNT     
(%W/W) 
1. Aluminium  0.016 
2. Chloride  0.043 
3 Calcium  0.034 
4. Borate  0.006 
5. Potassium  0.046 
6. Nitrate  0.012 
7. Iron 0.034 
8. Silver 0.008 
 
Quantitative Estimation Of Heavy Metals By ICP OES Method  
The quantification of the individual heavy metals was analyzed for the 
powdered mixture of Erythrina variegata Linn., by ICP – OES technique the 
following metals like arsenic, lead, cadmium were detected and quantified , results are 
given in the following table.  
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Table 13 : Quantitative Estimation Of Heavy metals  
S.No Element Results (ppm) Specification as per WHO 
Guidelines  
1. Mercury Not detected Not more than 0.5ppm 
 
2. Arsenic 0.023 Not more than 5.0ppm 
 
3. Lead 0.032 Not more than 10ppm 
 
4. Cadmium 0.001 Not more than 0.3ppm 
 
 
PHYTOCHEMICAL STUDIES  
Table 14 :  Percentage Yield Of Successive Extraction of  
Erythrina variegata Linn., 
S.NO EXTRACT METHOD 
OF 
EXTRACTION 
 
PHYSICAL 
NATURE 
COLOUR YIELD 
(%W/W) 
 
1. Petroleum 
ether 
 
Continuous Hot 
percolation method 
using Soxhlet 
apparatus 
Semisolid Yellowish 
green 
6.8 
2. Chloroform 
 
Semisolid Dark green 4.7 
3. Ethyl 
acetate 
Semisolid Dark brown 
in color 
3.7 
4. Ethanol Semisolid Brown in 
color 
5.6 
5. Aqueous Cold maceration Sticky Brown 
color 
4.8 
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QUALITATIVE PHYTOCHEMICAL ANALYSIS  
Table 15 :  Qualitative Phytochemical Analysis 
S.N
O 
    TEST OF 
CONSTITUE
NS 
PET 
ETHE
R 
CHLOR
O 
FORM 
ETHYL 
ACETAT
E 
ETHANO
L 
AQUEOU
S 
1 FLAVONOIDS + + + + + 
2 Alkaloids + + + + + 
3 Carbohydrates - - - - - 
4 Gums & 
Mucilage 
- - - - - 
5 Proteins & 
Amino acids 
- - - - - 
6 Fats and fixed 
oils 
+ + - - - 
7 Steroids - - + + - 
8 Glycosides - - - - - 
9 Phenols - - + + + 
10 Saponins - - - - - 
 
Note : + indicates presence, - indicates absence. 
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QUANTITATIVE ESTIMATION OF PHYTOCONSTITUENTS    
The Erythrina variegata Linn., was found to contain various phytochemical 
constituents and hence it is desirable to quantify few of them in order to establish a 
standard to maintain its quality. Among them the estimation of total Alkaloids, total 
Flavonoids and Phenolic content in the ethanol extract were decided to be taken as 
parameters. Samples were drawn from three random samples of Erythrina variegata 
Linn., was drawn and the content present in them were estimated.  
 
Table 16 : Quantitative estimation of Phytoconstituents  
 
S.NO PARAMETERS VALUES (µg/ml) 
1. Total Alkaloids 8.72µg/ml 
2. Total Flavonoids 5.46µg/ml 
3. Total Phenolics 6.86µg/ml 
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FLUORESCENE ANALYSIS  
Table 17 : Fluorescence Characteristics Of Powdered Sample Of   
Erythrina variegata  Linn., in  Short UV and Long UV. 
S.NO TREATMENT DAY LIGHT 
SHORT-UV 
(254nm) 
LONG-UV(365nm) 
1 Powder Green Brown Dark brown 
2 Powder + Water Dark green Brown Greenish brown 
3 
Powder + 
Ethanol 
Dark green Brown Dark brown 
4 
Powder + 1N 
HCl 
Yellow Yellow Greenish brown 
5 
Powder + 1N 
H2SO4 
Light  brown Brown Dark brown 
6 
Powder +  1N 
NaOH 
Green Dark green Dark green 
7 
Powder + 1N 
alcoholic KOH 
Dark green Brown Dark brown 
8 Powder + FeCl3 
Greenish 
brown 
Brown Dark brown 
9 
Powder + Acetic 
acid 
Greenish 
yellow 
Brown Dark brown 
10 
Powder + 
Ammonia 
Green Brown Greenish brown 
11 Powder + Iodine Green Brown Bluish brown 
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Table 18 : Fluorescence Analysis Of Various Extracts Of  
Erythrina variegata Linn., 
S.NO EXTRACTS DAY LIGHT SHORT-UV 
(254nm) 
LONG-UV 
(365nm) 
1 Petroleum ether  Dark green Dark green Dark green 
2 Chloroforum Pale green Dark green Dark green  
3 Ethyl acetate Light brown  Brown  Brown  
4 Ethanol  Brown  Dark brown Dark brown 
5 Aqueous  Brown  Dark brown Dark brown 
  
The powdered leaves and extracts of Erythrina variegata Linn., showed the absence 
of any fluorescence chromophore.   
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THIN LAYER CHROMATOGRAPHY OF EXTRACTS   
Table 19. TLC Solvents And Rf Value Of Various Extract 
S. 
no 
Chemical 
constituents 
Solvent system Extract No of 
spots 
Rf  value 
 
1. 
 
Alkaloids 
 
Toluene : 
Ethylacetate : 
Diethylamine 
(70:20:10) 
Pet ether 
Chloroform 
Ethyl 
acetate   
Ethanol  
Aqueous  
5 
3 
3 
3 
1 
0.2,0.32,0.34,0.36,0.43 
0.22,0.31,0.33 
0.22,0.32,0.34 
0.23,0.34,0.34 
0.23 
 
2. 
 
Flavonoids 
   
Ethyl acetate : 
Formic 
acid : Glacial 
Acetic 
acid : Water 
(100:11:11:26) 
Pet ether 
Chloroform 
Ethyl 
acetate   
Ethanol  
Aqueous 
1 
5 
3 
2 
0.73 
0.29,0.33,0.42,0.46,0.74 
0.3,0.47,0.76 
0.42,0.82 
 
 
 
3. 
 
Phenolic 
compounds 
 
Toluene : Ethyl 
acetate 
(93:7) 
Pet ether 
Chloroform 
Ethyl 
acetate   
Ethanol  
Aqueous 
1 
3 
2 
3  
 
0.88 
0.77,0.84 
0.77,0.93 
0.76,0.84 
 
 
4. 
 
 Steroids 
 
  Chloroform : 
Methanol 
(27:3) 
Pet ether 
Chloroform 
Ethyl 
acetate   
Ethanol  
Aqueous 
3 
4 
1 
5 
0.52,0.71,0.79 
0.4,0.48,0.6,0.72 
0.54 
0.39,0.48,0.52,0.71,0.87 
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Table 20 : TLC Of  Various Extracts 
TLC of five extracts 
TLC of Alkaloids TLC of 
Flavonoids 
TLC of Phenolic 
compounds 
TLC of Steroids 
    
 
HPTLC  FINGER PRINT PROFILE  
HPTLC Finger print Data of Ethanolic Extract of Erythrina variegata Linn., 
High performance thin layer chromatography (HPTLC) finger printing was performed 
with the ethanol extract of Erythrina variegata Linn.,  
Table No 21: Solvent System Of HPTLC analysis 
EXTRACT SOLVENT 
Ethanolic extract Chloroform : Methanol : Formic acid : 
Water 
(65:25:10:5) 
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Fig. 23 HPTLC finger print of Acoholic extract at 254 and 366nm 
                    
                               5µl          10µl                5µl         10µl   
                               at 254 nm                          at 366 nm 
             Fig 24.  HPTLC Chromatogram of Alcoholic Extract (5µl) at 254 nm   
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           Table 22 : HPTLC of Alcoholic Extract (5µl) at 254 nm   
Extract Solvent system Rf values 
Alcoholic 
extract 5µl 
 
 
 
Chloroform : 
Methanol : 
Formic acid : 
Water 
(65:25:10:5) 
 
 
 
0.11 
0.20 
0.31 
0.37 
0.42 
0.59 
0.74 
0.83 
0.85 
 
              Fig. 25 HPTLC of Alcoholic Extract (5µl) at 366  nm   
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Table 23 :  HPTLC of Alcoholic Extract (10µl) at 366 nm 
Extract Solvent system Rf values 
Alcoholic extract 10µl 
 
Chloroform : Methanol : 
Formic acid : Water 
(65:25:10:5) 
 
 
 
0.09 
0.17 
0.33 
0.37 
0.42 
0.59 
0.73 
0.82 
0.85 
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SELECTION OF ACTIVE EXTRACT  
IN – VITRO  ANTI – OXIDANT ACTIVITY  :  
                                           Table  24 DPPH ASSAY 
DRUGS % INHIBITION AT VARIOUS CONCENTRATION IC 50 
(µ g/ml) 100 g/ml 200 g/ml 400 g/ml 800 g/ml 1000 g/ml 
Diclofenac 
sodium 26.17±0.45 34.72±1.86 41.88±0.54 61.23±1.56 73.02±0.09 578 
Petroleum 
ether 15.45±0.15 17.52±0.71 22.76±0.56 25.04±2.43 38.48±0.65 1549 
Chloroform 4.64±0.52 7.68±1.06 19.53±0.67 26.48±1.46 39.99±1.84 1309 
Ethyl 
acetate 17.22±0.90 24.45±1.43 36.24±0.43 45.59±0.96 51.15±1.73 916 
Ethanol 24.23±2.80 35.07±1.08 47.95±0.67 63.64±1.87 65.86±2.34 489 
Aqueous 1.78±1.62 5.75±1.87 14.18±1.73 28.3±1.43 35.67±2.54 1388 
 
Fig. 26  In vitro DPPH Assay 
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TABLE 25 : HYDROGEN PEROXIDE SCAVENGING ACTIVITY  
 
EXTRACTS              % INHIBITION AT VARIOUS CONCENTRATIOIC 50 
(µ g/ml) 
10 µg/ml20 µg/ml40 µg/ml60 µg/ml80 µg/ml 100 µg/ml 
Standard 
(Ascorbic 
acid) 13.59 26.18 44.62 58.12 69.48 76.28 56.82 
Petroleum 
ether 3.14 6.32 8.24 12.36 18.23 20.35 252.53 
Chloroform 2.65 5.58 7.18 13.52 15.27 17.85 309.32 
Ethyl 
acetate  7.16 16.82 34.57 45.61 56.83 60.12 78.48 
Ethanol 12.48 24.63 45.81 57.59 66.18 74.56 59.78 
Aqueous  3.54 5.72 7.94 9.34 11.34 13.57 365.74 
  
Fig. 27 In vitro Hydrogen Peroxide Scavenging Assay 
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Body weight 
Table 26 : Changes in the body weight (g). 
Groups Initial weight   14
th
 day   28
th
 day   42
nd
 day     56
th
 day 
Group I 
Control 
157±1.04 165.67±0.82 173.67±0.74 176±0.73 172.34±0.68 
Group II 
Disease control
154±0.47 173±0.27 190.34±0.53 197.34±0.40 205.45±0.46 
Group III 
Standard 
158.64±0.72 174.67±0.5 185±0.62 177.34±0.89 176.67±0.91 
Group IV 
200 mg/kg  
158.67±0.72 171.67±0.85 184.54±0.36 188.67±0.4 187.16±0.35 
Group V 
400 mg/kg 
159.34±0.4 170.34±0.61 179±0.59 184.34±0.57 182.67±0.39 
  
                                          Fig. 28 Changes in body weight  
 
 
Table 27 : Changes In The Food Intake (g) 
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Groups 
Initial 
Weight 
14
th
 day 28
th
 day 42
nd
 day 56
th
 day 
Group I 
Control 
73 75 77 80 82 
Group II 
Disease control 
76 80 84 86 88 
Group III 
Standard 
78 81 83 82 81 
Group IV 
Low dose 
76 78 80 81 78 
Group V 
High dose 
74 76 75 78 74 
 
Fig.  29 Changes In Food Intake 
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VAGINAL EXFOLIATIVE CYTOLOGY   
Fig. 30 Working Table – Method Of Taking Vaginal Smear 
 
 
 
 
Fig. 31 Vaginal Smear Taking In Rat Using Pipette Method 
 
           
 
 
 
Fig. 32  Preparing Vaginal Smear In Room Temperature 
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TABLE 28 : VAGINAL EXFOLIATIVE CYTOLOGY DAY 1 to 10  
Groups 
Days 
S.no 
1 2 3 4 5 6 7 8 9 10 
 
 
Group I 
1 P M D P E M M D M D 
2 P E M D E M M D P P 
3 M D EP E M D EP P P M 
4 P -- D P E M D D P M 
5 P E M D D E M M EP P 
6 P M M D EP E M D D P 
 
 
Group II 
7 P E M P LP E M D M D 
8 D E M D D P P -- P M 
9 -- D D P E M M D M P 
10 D D P -- D P M D D P 
11 D P E M D P E M M D 
12 P E M D LP E -- D P M 
 
 
 
Group III 
13 M D D E M D -- M D P 
14 P -- D D P E D D D P 
15 E M D D P E D P P D 
16 P M D P E M D M P M 
17 M M D E M D EP P P M 
18 P E M P E M D D M D 
 
 
 
Group IV 
19 -- P E M D D P P P D 
20 D D E M D D P D P M 
21 -- E M E M D D M M D 
22 D D M -- D D D M M D 
23 P P -- -- E M M P P M 
24 P -- -- P E M D M D D 
 
 
Group V 
25 -- -- -- -- -- -- D D P -- 
26 D E M D D P E M D P 
27 -- -- -- -- -- -- M D P E 
28 M D E -- M D D P E M 
29 -- -- -- -- -- -- -- D D D 
30 P E -- D P E M D P E 
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TABLE 29 :  VAGINAL EXFOLIATIVE CYTOLOGY DAY 11 TO 19 
Groups 
Days 
S.no 
11 12 13 14 15 16 17 18 19 
 
 
Group I 
1 D M P P P P P M M 
2 M D P D P P P P P 
3 D M P D D D P P P 
4 M D P D D D D P P 
5 D D M P P P M D D 
6 D D D P P D P P P 
 
 
Group II 
7 P D M M D P P P M 
8 D M D P M D D D D 
9 D P P M D D D P P 
10 M D D P M D D D P 
11 D P M P P M D D D 
12 D D P P P M M D P 
 
 
 
Group III 
13 M M D P D D D P P 
14 P M D E M D D D D 
15 D M D D P P M M D 
16 D P M M M D P P M 
17 M P D -- -- M M D D 
18 D P M M D P P M M 
 
 
 
Group 
IV 
19 D D M P D P P M M 
20 D P M P D D P P M 
21 P M M M D P -- D P 
22 D D P M M M D D P 
23 M D D D P P P P M 
24 D P P -- P M M D P 
 
 
Group V 
25 D D M M D D D E M 
26 E M D -- D D P E M 
27 M D D P D E M D P 
28 D D P E M D P E -- 
29 P E M D P D P E M 
30 M M D M M D P P E 
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TABLE 30 : VAGINAL EXFOLIATIVE CYTOLOGY DAY 20 TO 29 
Groups Days  
S.no 
20 21 22 23 24 25 26 27 28 29 
 
 
Group I 
1 D D D D P P P M P E 
2 M M M D D D P D D E 
3 P P M M M D D D E M 
4 P M M D D D P P P E 
5 D D P P D D D D D D 
6 D D P P P D D D D EP 
 
 
Group 
II 
7 D D D P P M M D P LP 
8 P M M D D D D P D D 
9 P M D D D D P P P E 
10 P P M D D D P P -- D 
11 D D P P M M D D M D 
12 P D D D D P P P D LP 
 
 
 
Group 
III 
13 P P P M M M M D E M 
14 P P P P M M M D D P 
15 D D D D P P P M D P 
16 M D D D D P P P P E 
17 D D P P P -- M D E M 
18 M D D D D P -- P P E 
 
 
 
Group 
IV 
19 D D -- D P P M M M D 
20 M M M D D P P P M D 
21 P M M M D D D P E M 
22 P P P D M D D D -- D 
23 M M D P D P P M -- E 
24 D D P P D D P P P E 
 
 
Group 
V 
25 D M D E P E M D -- -- 
26 D D P E M D D P D D 
27 E D P P -- D P E -- -- 
28 D D D D E M D D -- M 
29 D E M P D P E M -- -- 
30 M D D P E M D D D P 
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TABLE 31 :  VAGINAL EXFOLIATIVE CYTOLOGY DAY 30 TO 38 
Groups 
Days 
S.no 
30 31 32 33 34 35 36 37 38 
 
 
Group I 
1 D P -- M -- D D P M 
2 M M M D -- D P -- -- 
3 D D M D -- M M D D 
4 P -- M D -- D D P M 
5 D D D D P M D D P 
6 M -- D D M -- D P -- 
 
 
Group II 
7 M -- D D -- P E M M 
8 -- M D D D P M M -- 
9 M D D P M D D P M 
10 P D M M P M D D P 
11 D -- E M M D D D E 
12 P P D D P M M -- -- 
 
 
 
Group III 
13 M M D P E M M D D 
14 P D P LP E M D P P 
15 -- P P M D D D P M 
16 M M D P M D D D P 
17 M --D D -- D M M D P 
18 M P P M M D D D -- 
 
 
 
Group IV 
19 P D D D P D M M D 
20 M P P P P M M D D 
21 D D D P P M M D P 
22 E D D P M D D D D 
23 M D D D P D D D M 
24 P D -- M M -- -- D P 
 
 
Group V 
25 D P E M M D D D P 
26 D D E M M D D -- P 
27 M M D E M D D P E 
28 E M M D D E E M D 
29 D D -- E -- D D D P 
30 E E D EP E M M D D 
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TABLE 32 :  VAGINAL EXFOLIATIVE CYTOLOGY DAY 39 TO 47 
Groups 
Days 
S.no 
39 40 41 42 43 44 45 46 47 
 
 
Group I 
1 M M D M P E M D D 
2 P E M D D P E M M 
3 D D E M M D D P E 
4 D E M D D P E M M 
5 E M D D P D E M D 
6 M D D D E M D D D 
 
 
Group II 
7 P E M M D D P E M 
8 D -- D P E M D D D 
9 D D M D D D P E M 
10 M D D D M E E M M 
11 M M M M D D E M M 
12 D M D P E M D D P 
 
 
 
Group III 
13 P E M M D D D P E 
14 E E M M D D D P P 
15 P E M D D P E M M 
16 E M -- M D D D P M 
17 E M M D D P E M M 
18 P E M M D D D P E 
 
 
 
Group 
IV 
19 D D P P M D D P M 
20 P E M M D D D P E 
21 D D D P D M M M D 
22 D P D D D D P P E 
23 M E P D D P E M P 
24 P D D M M D D D -- 
 
 
Group V 
25 E M D -- -- M D D P 
26 E M D E M D D P E 
27 M D D -- D P E M M 
28 P E M D D P P E M 
29 E M D -- P E M D D 
30 P E M M D D D P E 
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TABLE 33 :  VAGINAL EXFOLIATIVE CYTOLOGY DAY 48 TO 56 
Groups 
Days 
S.no 
48 49 50 51 52 53 54 55 56 
 
 
Group I 
1 P E E M M P D D P 
2 D D D P P D M M M 
3 M D D P P D E D D 
4 D D P P E M D P -- 
5 D D P E E M D D D 
6 P P P M M P E M -- 
 
 
Group II 
7 P P P P D E D M -- 
8 P P E M M P D -- M 
9 M P D P M P E M D 
10 P D P P D E D P D 
11 D D D P P D E D -- 
12 E E E M P P D P P 
 
 
 
Group III 
13 M M D D P P M M M 
14 E M M D D E M P D 
15 D D P P D P D -- P 
16 M D D P P D M M M 
17 D D P P D E D M D 
18 M M P P D E M M P 
 
 
 
Group IV 
19 M D D D E M P P D 
20 M M D D E M M M P 
21 D D P -- D E P D D 
22 M M P P D E D E D 
23 M D D P P D D M D 
24 P P E E M P M P D 
 
 
Group V 
25 E M M P P D -- D P 
26 M D P M M P E D D 
27 D D E M P D -- M M 
28 D D P P D D D E M 
29 P E M M P D -- D D 
30 M M D D E M M E E 
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STAGES OF ESTRUS CYCLE   
                                                    Fig 33.  Proestrus phase 
 
     Proestrus smears are characterized  by rounded, nucleated, epithelial cells are present.      
 
Fig.  34 Estrus phase 
 
                Estrus smears consist entirely of cornified cells and often non – nucleated.  
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Fig. 35 Met estrus phase 
 
Met estrus smears consists of large number of leucocytes and smaller numbers of mostly 
large, non – granular and non – nucleated epithelial cells.  
                                                   Fig. 36  Diestrus phase 
                
Di – estrus smears consists mainly of Lecocytes but with quite variable numbers of epithelial 
and small cornified cells.  
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TABLE 34  :  BLOOD GLUCOSE 
Groups Mean value 
Group I 
Control 
110.34±0.64*** 
Group II 
Disease control 
152.83±0.92 
Group III 
Standard 
118.83±0.94**** 
Group IV 
200mg/kg 
125.5±0.94**** 
Group V 
400mg/kg 
122.5±0.67**** 
  
                                              Fig. 37 Blood Glucose Level  
 
               
Values are means ±SEM, (n=6) ****p<0.0001 versus disease control, Group I – 
Control, Group II – Disease control, Group III – Standard, Group IV – Low dose (200mg/kg 
body weight of extract), Group V – High dose (400mg/kg body weight of extract), SEM – 
Standard error of mean. 
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TABLE  35  : LIPID PROILE 
     Groups          TC         TG        LDL       HDL 
Group I 
Control 
53.34±0.43**
 
126.17±0.89** 46.25±0.56*** 35.84±0.6*** 
Group II 
Disease control 
61.83±0.92
 
142±0.78 43.91±0.49 20.67±0.36 
Group III 
Standard 
29±0.35***
 
102.167±0.79*** 27.34±0.67**** 25.67±0.37* 
Group IV 
200mg/kg 
28.67±0.69*** 100.67±0.62**** 27.5±0.48**** 26.34±0.43* 
Group V 
400mg/kg 
27.34±0.72***
 
105.84±0.9**** 27.91±0.47**** 28.5±0.31** 
  
Values are mean ±SEM, (n=6) ****p<0.0001, ***p<0.001,**<0.005  versus disease control, 
Group I – Control, Group II – Disease control, Group III – Standard, Group IV – Low dose 
(200mg/kg body weight of extract), Group V – High dose (400mg/kg body weight of extract), 
SEM – Standard error of mean.  
Fig. 38  Lipid Profile 
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ISOLATED ORGANS 
 
                        
 
 
 
 
 
 
Fig. 39 Ovary and Uterus of Group I          Fig. 40 Ovary and Uterus of group II                             
 
Fig. 41 Ovary and Uterus of Group III 
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Fig. 42  Ovary and Uterus of Group IV 
             
                                      
Fig. 43 Ovary and Uterus of Group V 
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WEIGHT OF REPRODUCTIVE ORGAN : 
 TABLE 36 : CHANGES  OF  OVARY AND UTERUS  WEIGHT  IN  RAT  
S.NO GROUUPS 
OVARY 
WEIGHT 
UTERUS 
WEIGHT 
1.  
Group I 
Control 
50.45±4.02 67.54±2.48 
2.  
Group II 
Disease control 
68.58±2.44 115.31±9.57 
3.  
Group III 
Standard 
57.21±2.62 79.06±1.42 
4.  
Group IV 
200 mg/kg 
60.12±1.7 71.8±1.18 
5.  
Group V 
400 mg/kg 
62.45±2.81 84.04±1.36 
 
                                            Fig. 44 Reproductive Organ Weight  
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HISTOPATHOLOGICAL  EXAMINATION  OF  GROUP  I : (CONTROL) 
 
Fig. 45  Section of Ovary                                              Fig. 46  Section of  Uterus 
 HISTOPATHOLOGICAL EXAMINATION OF GROUP II         
(DISEASE CONTROL)     
             
     
                  
 
 
        Fig. 47  Section of Ovary                                  Fig. 48  Section of Uterus 
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HISTOPATHOLOGICAL EXAMINATION OF GROUP III (STANDARD) 
 
                                                 Fig. 49  Section of  Ovary  
 
                                                           Fig. 50  Section of Uterus 
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HISTOPATHOLOGICAL  EXAMINATION  OF  GROUP  IV (200 mg/kg) 
               
 
 
 
 
 
Fig. 51 Section Of  Ovary Overview 
             
        Fig.53 Section of Uterus                      Fig.52  Section Ovary Showing Secondary  
                                                                                              Follicles      
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HISTOPATHOLOGICAL  EXAMINATION   OF  GROUP  V (400 mg/kg) 
 
     
Fig. 54  Section Ovary 
 
         
                 Fig. 55   Section Ovary                             Fig. 56  Section of Uterus 
 
RESULTS AND DISCUSSION 
 
Depar tment of Pharmacognosy, COP, MMC, Chennai -03  Page 122 
 
ISOLATION OF PHYTOCONSTITUENTS  USING COLUMN 
CHROMATOGRAPGY   
Fig. 61  Column Chromatography Experiment In Lap 
                                      
 
ISOLATION OF COMPOUND BY COLUMN CHROMATOGRAPHY: 
COLUMN CHROMATOGRAPHY 
Characterization of isolated compound 
Physical properties of the isolated compounds are evaluated, such as 
 Colour : Light Brown  
 Nature : Semisolid 
 Solubility : Soluble in Ethanol and Water A 
 TLC Rf value : 0.73 
 Chemical test : Yellow to colourless on addition of  acid     
                                     (Alkaline reagent test) 
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Spectral analysis: 
The compound (C-1 and C-2) obtained from ethanolic extract have identified 
and spectral datas were depicted in the figure below.  
Compound 1 
IRυcm-1: Nujol mull           FIG 62. IR SPECTRUM 
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TABLE 41. INTERPRETATION OF IR SPECTRUM  
WAVE NUMBER INTENSITY TYPE 
3387.00 Broad C = O Stretching 
2922.16 Sharp C = H Stretching 
2862.72 Sharp C = H Stretching 
1714.72 Weak band C = N Stretching 
1639.49 Moderate N - H Bending 
1344.38 Sharp C – H Bend in plane 
1259.52 Weak band O – H Bending 
1074.35 Moderate C – O Stretching 
1033.85 Moderate C – O Stretching 
798.53 Sharp C – H Rocking 
459.06 Moderate C = O Stretching 
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GC-MS ANALYSIS 
FIG 63. STRUCTURE OF N-HEXADECANOIC ACID 
 
 
Compound name: N-Hexadecanoic acid 
Molecular weight: 256 
Molecular formula: C16H32O2 
FIG 64. STRUCTURE OF ERUCIC ACID ‘ 
 
  
 
Compound name: Erucic acid 
Molecular weight: 338 
Molecular formula: C22H42O2 
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FIG 65. MASS SPECTRUM OF N- HEXADECONIC ACID 
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FIG 66. MASS SPECTRUM OF ERUCIC ACID 
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SURVEY OF POLYCYSTIC OVARIAN DISEASE  
The study population comprised about 232 girls. The study reveal that among 
68 girls of 17-19 years of age group 8 of them were with symptoms of PCOD. About 
42 girls of 20-22 years age group 7 girls were with symptoms of PCOD. About 35 
girls of 23-25 years age group 5 girls were with symptoms of PCOD. About 27 girls 
of 26-28 years age group 4 girls were with symptoms of PCOD. About 26 girls of 29-
31 years age group 2 girls were with symptoms of PCOD. About 31 girls of 32-35 
years age group 1 girls were with symptoms of PCOD.      
               Table 37 : Total number of Students Having Irregular Periods  
S.no Age 
Total number 
of students 
studied 
Total no students 
having irregular 
periods 
% of students with 
PCOS 
1 17-19 68 12 17.6 
2 20-22 42 8 19 
3 23-25 38 6 15.7 
4 26-28 27 4 14.8 
5 29-31 26 3 11.5 
6 32-34 31 2 6.45 
 
Fig. 57  Total Number Of Students Having Irregular Periods 
 
Totally 35 girls in different age group to be having irregular menstrual cycles. 27 girls were 
detected with polycysts in their ovaries.  
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Table 38 : Total Number Of Students Having Hirsutism 
S.no Age 
Total number of 
students 
Total number of 
students having 
Hirsutism 
% of students 
having Hirsutism 
1 17-19 68 6 8.8 
2 20-22 42 4 9.52 
3 23-25 38 3 7.89 
4 26-28 27 4 14.81 
5 29-31 26 3 11.5 
6 32-34 31 2 6.45 
 
Fig. 58  Total Number Of  Students Having Hirsutism 
 
                                  22 girls were found to be with Hirsutism  
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Table 39 :  Number of students Identified with PCOD Syndrome: 
S.no Age Total number of 
students 
surveyed 
No of students 
identified PCOS 
% of students 
with PCOS 
1 17-19 68 8 11.76 
2 20-22 42 7 16.6 
3 23-25 38 5 13.15 
4 26-28 27 4 14.81 
5 29-31 26 2 7.69    
6 32-34 31 1 3.22 
 
Fig. 59  Number Of Students Identified with PCOS 
 
Number students identified PCOS: 27 
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Table 40 : Mean weight (kg), Mean Height (cm), BMI 
S.no Age Mean Height 
(cm) 
Mean weight 
(kg) 
BMI 
1 17-19 150.6 55.41 24.5 
2 20-22 155.25 53.62 25.28 
3 23-25 153.6 54.74 26.8 
4 26-28 155 53 23.4 
5 29-31 152.75 57.12 26.1 
6 32-34 151.8 59.27 17.12 
 
Fig.  60 Mean weight (kg), Mean Height (cm), BMI 
 
                                          
The mean BMI of girls in age groups 17–19, 20 – 22, 23 – 25, 26 – 28,29– 31,  
and 32 – 34 were 24.5, 25.28, 26.8, 23.4, 26.1 and 27.12 respectively.  
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DISCUSSION 
PHARMACOGNOSTICAL STUDIES 
Pharmacognostical studies play a key factor in establishing the authenticity of 
the plant material. The botanical identity of the leaves was established by examining 
its anatomical features.   
The anatomical examination of Erythrina variegata Linn., leaves exhibited 
important microscopical features like vascular bundle, schlernchyma cells, 
parenchymatous cells, trichomes, stomata and prism like calcium oxalate crystals.  
The leaf exhibits thick midrib and uniformly thick and smooth lamina. The 
midrib consists of wide, conical, short thump and wide semicircular abaxial part of 
the midrib. The midrib is 1.1mm thick and the abaxial semicircular part in 1mm wide.  
The upper portion of midrib shows vascular bundles which has a cluster of 
large angular, thick walled cells. Three vertically elongated pholem units present in 
adaxial side of the leaf and sclerenchyma cells placed above the adaxial medium 
bundle.  
In  lower portion epidermis of the  midrib consists of small squarish the cell 
walled cells 2mm wide, angular, thick walled and compact parenchyma cells.  
In the midrib the calcium oxalate crystals are drusen located in the 
parenchyma cells inside the adaxial epidermal layer.  
Powder microscopy showed the presence of paracytic stomata, glandular 
trichome, anticlinal walls, double cystolith these features  can be employed for inter 
specific identity of drugs.  
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Leaf constant values  such as stomatal number, stomatal index, vein islet 
number and vein termination number was carried out.  
The linear measurements of length and width of the calcium oxalate crystals 
were carried by using stage micrometer and eye piece micrometer and the range for 
length and width of the calcium oxalate crystals is as follows Length 125µ, 298µ, 
572µ and Width 12.8µ, 16.4µ, 26.8µ.  
Histochemical  reactions were carried out on the different sections of the 
leaves using various chemical reagents. The presence of lignin, alkaloid, starch is 
identified.  
Physiochemical parameters are mainly used in judging the purity and quality 
of the powdered drug. Ash values of a drug given an idea of the earthy matter or 
inorganic elements and other impurities present along with the drug.  
Ash values are mainly used in judging the purity and quality of the drug is the 
indicative of contamination, substitution and adulteration. The total ash usually 
consists of carbonate, phosphate and silicates.  
Total ash was found to be 9.48±0.56%w/w. The acid insoluble ash indicates 
contamination with siliceous materials like earth and sand. The values was found to 
be 6.9±0.48%w/w.  
             The water soluble ash is the good indicator of water soluble salts. The value 
of water soluble ash was found to be 4.73±74%w/w. Sulphated ash is obtained by 
treatment with dil.sulphuric acid where the oxides are converted to sulphates. The 
values was found to be 5.6±0.75%w/w.  
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The alcohol soluble and water soluble extractives were found to be 
41.37%w/w and 24.65%w/w respectively. Ether soluble extractive was found to be 
11.54%w/w. 
The alcohol soluble extractive value indicates the presence of considerable 
amount of polar organic salts present in the plant. These constants would help to 
identify and to standardize the plant by future researchers.  
Loss on drying determines the amount of moisture content of any kind that can 
be driven off under conditions specified.  
The loss on drying was found to be 5.11%w/w. The leaf powder showed 
absence of foaming index, mucilage index and swelling index.  
The qualitative analysis of heavy metals and in organic elements were carried 
out. The heavy metals are present within the limits.  
The percentage compositions of different inorganic elements were determined. 
The presence of inorganic elements like, aluminium, chloride, calcium, iron, borate, 
potassium, nitrate and silver was found to be 0.016, 0.043, 0.034, 0.036, 0.006, 
0.046, 0.012 and 0.008%w/w respectively.  
The detailed Pharmacognostical studies on the leaves of Erythrina vaiegata 
Linn., provides information on the standardization parameters and physiochemical 
parameters which is essential for the identification of raw material and also used to 
differentiate the plant from its adulterants and substitutes.  
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PHYTOCHEMICAL STUDIES 
Since herbal medicines are prepared from materials of plant origin they are 
sometimes to prone deterioration and variation in composition. Hence, before 
proceeding to clinical studies, scientists need a tool to authenticate plants and also to 
detect their potency.  
A lot of analytical techniques have been developed for quality control of drugs 
from plant origin. Therefore it is very important to undertake Phytochemical 
investigations along with biological screening to understand therapeutic efficacy of 
medicinal plants and also to develop quality parameters.  
In this analysis different polarity of Phytoconstituents were sorted out from the 
coarsely powdered leaves of Eryhtrina variegata Linn., by using solvents of 
increasing polarity like Petroleum ether, Chloroform, Ethyl acetate, Ethanol and 
Aqueos by using successive solvent extraction.  
Successive extractive values revealed the solubility and polarity participants of 
the metabolites in the leaf powder. Percentage yield of various extracts were as 
follows, Petroleum ether (6.8%w/w), Chloroform(5.7%w/w), Ethyl acetate 
(4.6%w/w), Ethanol (7.2%w/w) and Aqueous(3.5%w/w).  Ethanolic extract showed 
high extractive yield among other extracts.  
Qualitative Phytochemical analysis was performed initially with different 
respective chemical detecting agent to detect the phytoconstituents nature and their 
presence in each extract and powder.  
Petroleum ether extract showed the presence of FLAVONOIDS, Alkaloids, fats and 
fixed oils. Chloroform extract showed the presence of  FLAVONOIDS, Alkaloids, 
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fats and fixed oils, phenols. Ethyl acetate extract showed the presence of 
FLAVONOIDS, Alkaloids, steroids, phenols. Ethanol extract showed the presence of 
FLAVONOIDS, Alkaloids, steroids, phenolic compounds. The aqueous extract 
showed the presence of  FLAVONOIDS, alkaloids.  
Quantitative estimation of alkaloids, FLAVONOIDS, phenolic compounds 
and fluorescence analysis of extracts were carried out. Total alkaloid content, 
flavanoid content and phenolic content were done by ethanolic extract were done by 
values were found to be 8.72µg/ml, 5.46µg/ml, and 6.86µg/ml for content 
respectively.  Fluoroscence characteristics o powdered sample and extract was done 
which showed absence of fluorescence chromophore. 
Qualitative chromatographic analysis of all the five extracts were done using 
Thin Layer Chromatography to separate and identify the single or mixture of 
constituents present in each extract.  
High Performance Thin Layer Chromatography (HPTLC) finger printing was 
performed with the Ethanol extract of the leaves of Erythrina variegata Linn., There 
were 9 peaks observed with different Rf values and different heights. Percentage of 
areas were also obtained from chromatogram.  
 Isolation of phytoconstituents was carried out using Column Chromatography 
to elute the individual compounds. They were further subjected for spectral analysis.  
PHARMACOLOGICAL STUDIES  
Pharmacological studies were carried out for assessing the Letrazole induced 
Polycystic Ovarian Disease activity of the plant Erythrina variegata Linn.,   
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The active extract was selected on the basis of in vitro anti oxidant activity. 
Accordingly the ethanolic extract with potential anti oxidant activity was selected for 
in vivo study. 
Based on the acute toxicity studies, previously reported 1/10
th
 and 1/5
th
 (200 
and 400 mg/kg) of the maximum tolerated dose (2000 mg/kg B.W) were selected for 
the in vivo studies.  
The parameter studied were body weight, food intake, vaginal exfoliative 
cytology, Blood glucose, Lipid profile, reproductive organ weigh, histo-pathological 
examination of ovary and uterus was done. 
The body weight of the different groups of rat were noted. The body weight of 
the Polycystic Ovarian Disease induced group shows in increase in body weight 
compared to the normal control group. After treatment the body weight of the Group 
IV and Group V was found to decrease in body weight. This was compared to the 
standard group which showed change in body weight. This shows that the ethanolic 
extract is effective in normalizing the enhanced body weight.  
The food intake of different groups of rat were noted. The food intake of the 
Polycystic Ovarian Disease induced group shows in increase in food intake compared 
to the normal control group. After treatment the food intake of Group IV and Group V 
was found to decrease in food intake this was compared to the standard group which 
change in food intake. This shows that the ethanolic extract is effective in normalizing 
the enhanced body weight.  
In the present study, Letrazole – aromatase inhibitor, was used to induce 
Polycystic Ovarian syndrome in female Wister rats. The working of this model was 
RESULTS AND DISCUSSION 
 
Depar tment of Pharmacognosy, COP, MMC, Chennai -03  Page 138 
 
confirmed by regular examination of vaginal smears and presence of persistent 
vaginal cornification.  
The nature of cell types in the vaginal smear determines the stage of the estrus 
cycle. Letrazole-treated rats showed irregularity in its estrus cycle determination and 
which changed to normal sequence of estrous cycle after treating the rats with the 
Ethanolic extract of Erythrina variegata Linn., The restored estrus cycle indicating 
the recovery of anovulation to normal ovary functions.  
The Blood glucose level was determined in all groups. The Blood glucose 
level was found to increase to a value of 152.83±0.92 in Disease control. Ethanol 
treated group 122.5±0.94mg/dl  lowered the elevated level of glucose to 118.83±0.94 
mg/dl. Which was compared to standard which showed a value of 118.83±0.94. 
In the present study, lipid profile, PCOS induced groups showed notable 
increase in TC, TGs, LDL and decrease in HDL levels. Ethanolic extract of Erythrina 
variegata Linn., displayed antihyperlipidemic action by considerably decreasing the 
enhanced serum TC, TGs, LDL while increasing HDL levels. This showed that the 
ethanolic extract is effective in normalizing the enchanced lipid levels.  
The ovary and uterus weight of the different groups of rat were noted. The 
ovary and uterus weight of Polycystic Ovarian Disease group shows in increase in 
value when compared to the normal control group. After treatment the Group IV and 
Group V was found to decrese in value. This was compared to the standard group 
which showed decrease  in ovary and uterus weight due to the effect of standard drug. 
This shows that the ethanolic extract is effective in normalizing the enchanced ovary 
and uterus weight.  
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The histopathological results of control ovary show normal ovarian 
architecture with matured secondary follicles and oocyte. The fresh corpus luteum 
indicates the presence of previous ovulation.   
Letrazole treated rats exhibited numerous subcapsular cysts, with a very thin 
or no granulosa layer. Corpora lutea were completely absent indicating anovulation 
and irregular estrus cycle. Few follicles were observed at their early stages of 
development. In addition, they were accompanied with atretic follicles containing 
fluid filled antrum and higher incidence of pyknotic granulosa cells.  
Standared  treatment led to disappearance of cysts and appearance of healthy 
follicles and corpora lutea.  
Sections from Group IV of Ethanolic extract of Erythrina variegata Linn., 
(200mg/kg) group exhibited follicles large in size and many corpora lutea present. 
Also antral follicles with clearly differentiated oocyte, granulosa cell layer, corona 
radiate and theca cells were observed. Group V of Ethanolic extract of Erythrina 
variegata Linn., (400mg/kg) group showed secondary follicles with oocyte were 
visible in the histopathological results. It also showed a fresh and thick corpous 
luteum indicates ovulation.  
In treated group decrease incidence of pkynotic granulose cells. Varying 
number of corpora lutea were seen suggesting ovulation and normal estrus cyclicity. 
Follicles at different stages of development with oocyte are clear, visible granulosa 
cell layer were observed. Ovarian cortex appeared normal with many follicles.  
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Isolation of compounds were done using Column Chromatography is done. 
The isolated compounds were identified using IR and GC – MS analysis and were 
found  to  be Erucic acid and N-Hexadecanoic acid. 
This survey will explore the complex mechanism behind the manifestation of 
PCOS and how these, and other factors, may make diagnosis difficult. In order to 
thoroughly understand these aspects of PCOS, the causes, symptoms and treatments 
were explored.  
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SUMMARY AND CONCLUSION 
Herbal medicines are found to be effective in treatment of various ailments but 
the major lacuna is lack of proper scientific validation. Hence the present study is 
aimed at investigating the selected plant Erythrina variegata Linn., for the Polycystic 
Ovarian Disease.  
The plant Erythrina variegata Linn., belonging the family Fabaceae, is 
claimed to be useful for Emmenagogue, but the claim has not been scientifically 
validated. 
Authentication of the plant material plays a key role in Pharmacognostical 
studies. The plant Erythrina variegata Linn., was collected from Karur district, 
Pillapalayam village and Authenticated by Prof. P. Jayaraman, Ph.D., Plant Anatomy 
Research Centre, Chennai.  
The parameters studied were Macroscopy, Microscopy, Powder microscopy, 
Leaf constants, Linear measurements, Histochemical studies and Physiochemical 
constants to establish data for proper authentication and detection of adulterants.  
The qualitative and quantitative analysis were carried out to identify inorganic 
elements present in the plant. 
The qualitative and quantitative analysis of toxic heavy metals like Cadmium, 
Arsenic, Lead and Mercury were within the WHO limits and ensure the safety of the 
drug.  
In Phytochemical analysis, extraction is the first step involved. The coarse 
powder was extracted by Petroleum ether, Chloroform, Ethyl acetate and Ethanol by 
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successive solvent extraction by hot percolation method and aqueous extract by cold 
maceration.  
The preliminary Phytochemical screening of various extract of the plant have 
revealed the presence of constituents like alkaloids, flavanoids, steroids and fats & 
fixed oils.  
Quantitative estimation of alkaloids, flavonids and phenolics compounds was 
done. 
Fluoroscence analysis of powder and extract was done and it did not any 
fluorescent chromophore. 
 TLC and HPTLC analysis of Ethanolic extract was carried out to identify 
Phytoconstituents present. 
In – vitro studies – DPPH assay and Hydrogen peroxide radical Scavenging assay 
were performed to select the most Bio – active extract. Based on this the ethanol 
extract was selected for In-vivo studies.  
Acute toxicity studies revealed that the extract was safe up to the dose of 2000 
mg/kg and the LD50 values in the range of 2000 mg/kg. Hence 200 mg/kg and 400 
mg/kg was selected for the study. 
Polycystic Ovarian disease was assessed by Letrazole induced Polycystic 
Ovarian disease method. 
 The parameters studied were Body weight changes, Food intake, Vaginal 
exolitative cytology, Blood sugar level, Lipid profile (TC, TGs, LDL, HDL), 
Reproductive organ weight and Histopathological studies. Ethanolic extracts showed 
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decrease in the elevated level of body weight, food intake, triglycerides, total 
cholesterol, LDL  and reproductive organ weight and increase in the HDL level. 
All the parameters revealed the effective role of ethanolic extract in Polycystic 
Ovarian disease activity which was comparable to the standard.  
 In the study of Polycystic Ovarian disease activity the Ethanolic extract shows 
significant activity in both In – vitro and In – vivo models. 
  Ethanolic  extract of Erythrina variegata Linn., showed many beneficial 
effects similar to standard drug in treating PCOS condition and inducing ovulation.  
 These effects may be ascribed to its multiple pharmacological activities like 
estrogenic, antihyperlipidemic, antioxidant and hypoglycemic effects which could be 
useful in managing PCOS condition and prevent ovarian cell dysfunction, ovulation 
and thereby improving fertility. 
Together broad spectrum biological effects of Ethanolic extract of Erythrina 
variegata Linn., make it a promising drug for treating clinical and pathological 
abnormalities in PCOD condition.   
Isolation of compound using Column Chromatography was carried out to elute 
the individual compounds. They were further subjected for spectral analysis like IR 
and GC – MS. The isolated compound was proposed to be N-Hexadecanoic acid and 
Erucic acid. 
 Survey of Polycystic Ovarian Disease among the girls students and working 
women in the age group 17-34 years was done , to collect the data and  statistical 
measurements done. The research on all of these aspects of PCOD will inform the 
public about how PCOD can affect them and their loved ones.  
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